

Human Medicines Regulations 2012

Advisory Bodies

British Pharmacopoeia Commission

Annual Report 2025

Published July 2026



Medicines and Healthcare products Regulatory Agency

**HUMAN MEDICINES REGULATIONS 2012
ADVISORY BODIES**

British Pharmacopoeia Commission

**ANNUAL REPORT
2025**

**Laid before Parliament pursuant to
Part 2, Regulation 12(4) of
the Human Medicines Regulations 2012**



© Crown copyright 2026

Published by the Medicines and Healthcare products Regulatory Agency

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at <https://www.gov.uk/mhra>

Any enquiries regarding this publication should be sent to the Medicines and Healthcare products Regulatory Agency at:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

ISBN 978-1-8384147-5-7

Printed on paper containing 40% recycled fibre content minimum

Printed in the UK by HH Associates Ltd. on behalf of the Controller of His Majesty's Stationery Office

Table of Contents

BRITISH PHARMACOPOEIA COMMISSION ANNUAL REPORT FOR 2025	8
Introduction	8
The membership	8
Code of practice	8
Meetings.....	9
Secretariat.....	9
Laboratory	9
Costs	9
Progress and publications	10
British Pharmacopoeia 2025	10
British Pharmacopoeia 2026	10
British Pharmacopoeia (Veterinary) 2026	11
British Approved Names 2026	11
Digital Publications.....	11
Prices and Availability	12
Future Publications	12
Biological Medicines.....	13
Unlicensed Medicines	13
Herbal and Complementary Medicines	14
Nomenclature	14
Sustainability	15
Liaison with Other UK Organisations	15
Laboratory	16
BP Reference Materials	16
European Pharmacopoeia	16
International Liaison and Collaboration	17
Acknowledgements	19
APPENDIX I.....	20
BRITISH PHARMACOPOEIA COMMISSION PUBLICATIONS DURING 2025	20
APPENDIX II.....	21
Membership of the British Pharmacopoeia Commission.....	21
Membership of the Anti-Infective Medicines Expert Advisory Group (AIM EAG)	22
Membership of the Biological and Biotechnological Products Expert Advisory Group (BIO EAG).....	23
Membership of the Herbal and Complementary Medicines Expert Advisory Group (HCM EAG)	24
Membership of the Medicinal Chemicals Expert Advisory Group (MC1 EAG).....	26

Membership of the Medicinal Chemicals Expert Advisory Group (MC2 EAG).....	27
Membership of the Medicinal Chemicals Expert Advisory Group (MC3 EAG).....	28
Membership of the Pharmacy and Nomenclature Expert Advisory Group (PCN EAG)	29
Membership of the Unlicensed Medicines Expert Advisory Group (ULM EAG).....	30
Membership of the Panel of Experts for Blood Products (BLP Panel)	30
Membership of the Panel of Experts for Excipients (CX Panel)	31
Membership of the Panel of Experts for Inorganic and General Chemicals (IGC Panel).....	31
Membership of the Panel of Experts for Microbiology (MIC Panel).....	32
Membership of the Panel of Experts for Radioactive Materials (RAD Panel)	32
Membership of the Panel of Experts for Veterinary Medicines (VET Panel).....	33
Membership of the Panel of Experts for Veterinary Immunological Products (VIP Panel).....	33
Membership of the Analytical Quality by Design Working Party (AQbD WP)	34
Membership of Advanced Therapy Medicinal Products Working Party (ATMP EAG)	35
Membership of Alternative Approaches for Documentary and Physical Standards for Biotechnological Products Working Party (BIO-DPS WP).....	37
EUROPEAN PHARMACOPOEIA COMMISSION – Members of the United Kingdom Delegation During 2025.....	37
DECLARATION OF INTERESTS	38

BRITISH PHARMACOPOEIA COMMISSION

BRITISH PHARMACOPOEIA COMMISSION

ANNUAL REPORT FOR 2025

Introduction

The British Pharmacopoeia Commission (BPC), appointed under Part 2 of the Human Medicines Regulations 2012 (the 2012 Regulations), is responsible under regulation 317 for preparing new editions of the British Pharmacopoeia (BP) and the British Pharmacopoeia (Veterinary) (BP Vet) and for keeping them up to date. It also provides advice to the United Kingdom (UK) delegation to the European Pharmacopoeia Commission (EPC), of which the UK is a member by virtue of its obligations under the Convention on the Elaboration of a European Pharmacopoeia (European Treaty Series No. 50). Under regulation 318 of the 2012 Regulations, the BPC also selects and devises names to be used at the head of monographs, which are subsequently published as British Approved Names (BAN).

It is of paramount importance that the medicines received by patients are safe, effective and of a suitable quality. The BP and BP(Vet) contribute significantly to the quality of medicines for human use and for animal use by providing publicly available, legally enforceable standards which are part of the overall system for safeguarding the health of patients in the UK and beyond. The BP is used across the globe and referenced in the legislation of several countries.

The membership

A list of members of the BPC during 2025 is shown in Appendix II.

The final term of office for one member of the BP Commission ended on the 31st December 2025. A campaign to recruit a new member was carried in collaboration with the Department of Health and Social Care Appointments Team during the year.

A list of members of the supporting Expert Advisory Groups (EAGs), Panels of Experts and Working Parties (WPs) for 2025 is given in Appendix II.

Code of practice

1. Members of the BPC are required to comply with the Medicines and Healthcare products Regulatory Agency (MHRA) Code of Practice on Identifying, Declaring and Managing Interests. This new Code of Practice was launched on 8th September 2022 and replaced the former BPC Code of Practice. Members of the EAGs, Panels of

Experts and WPs are also required to comply with the new Code of Practice. Members of the BPC and its supporting EAGs, Panels of Experts and WPs are permitted to hold personal interests in the pharmaceutical industry, with the exception of the Chair of the BPC. This allowance ensures that the BPC and its supporting groups benefit from the practical insights and up-to-date knowledge that these technical members bring from their active roles in the industry. The Code of Practice link can be found here [Code of Practice for the British Pharmacopoeia Commission and other expert advisory committees](#).

Meetings

2. The BPC met three times during 2025. Fifteen meetings of the EAGs, Panels of Experts and WPs were also held during the year, together with several meetings of the four working parties of the EAG Advanced Therapy Medicinal Products (EAG ATMP).
3. Summary Minutes of the meetings of the BPC and its EAGs, Panels of Experts and WPs can be found on the BP website ([Meetings and minutes - British Pharmacopoeia](#)).

Secretariat

4. The BP Secretariat is based at 10 South Colonnade, Canary Wharf, London E14 4PU.

Laboratory

5. The Laboratory is based at the LGC Group National Laboratories (Guildford) and is managed under a collaboration agreement with LGC Ltd.

Costs

6. For each meeting that they attend, members of the BPC are entitled to claim a taxable attendance fee of £325 (Chair's fee, £500). Members of the EAGs, Panels of Experts and WPs are entitled to claim a taxable attendance fee of £200 per meeting attended (Chair's fee, £325). Travel and subsistence costs are also payable within MHRA guidelines.

Progress and publications

British Pharmacopoeia 2025

7. Following publication of the BP 2025, three online updates were issued providing users with the texts of Supplements 11.6 to 11.8 of the 11th Edition of the European Pharmacopoeia.

British Pharmacopoeia 2026

8. The BP 2026 was published in August 2025. This new edition is available as a package containing the five volumes of the BP 2026, the one volume of the BP (Vet) 2026 and access to the electronic versions of both publications (online BP and offline download format).
9. This new edition contains over 4000 monographs for substances and articles used in the practice of medicine and almost 500 infrared reference spectra, together with the necessary appendices and supporting material. The effective date of the BP 2026 is 1st January 2026.
10. All monographs published within in the 11th edition of the European Pharmacopoeia, as amended by Supplements 11.1 to 12.8, are included either in this printed edition of the BP or, where appropriate, in the associated printed edition of the BP (Vet). Monographs of the European Pharmacopoeia are clearly distinguished from those of national origin by means of a chaplet of stars that appears alongside the monograph title. Where appropriate, statements of relevance to UK usage, such as Action and Use and the list of BP preparations, have been added to the European Pharmacopoeia monographs.
11. The BP 2026 contains 19 new monographs and texts of national origin which were not published in previous editions. A significant number of national monographs were amended in respect of technical or editorial content (131 in total) and the titles of 9 national monographs and one appendix name were amended in this edition.
12. Two new Appendices: Appendix VIII. Capillary Isoelectric Focusing for Recombinant Therapeutic Monoclonal Antibodies and Appendix XX J. Extractable Elements In Plastic Materials for Pharmaceutical Use have been incorporated by means of this edition.
13. Four new Supplementary Chapters were added by means of this edition, SC I C2. Pyrogenicity; SC IV N. Additional Information On Gene Therapy Medicinal Products for Human Use; SC IV R2. Design of Experiments and SC IV X. Phase Therapy Medicinal Products.

14. Three national monographs for products no longer marketed were omitted from the BP 2025 following consultation. In accordance with Regulation 252(2)(c) of the 2012 Regulations, omitted monographs continue to remain in force.

British Pharmacopoeia (Veterinary) 2026

15. The BP (Vet) 2026 was published as a companion volume to the BP 2026 in August 2025. This new edition contains monographs, infrared reference spectra and a number of appendices relating to materials used solely in veterinary medicine. The effective date of the BP (Vet) 2026 is 1st January 2026.

British Approved Names 2026

16. BAN 2026 was published in August 2025. This defines 39 new chemical and biological entities that are used in medicines in the UK. The majority of the new names are for active substances used in medicinal products that have not previously been marketed in the UK.

Digital Publications

17. The BP 2026 publications can be accessed through the online version (pharmacopoeia.com) and the offline download edition. Both formats have been updated to include the European Pharmacopoeia issues 12.1 and 12.2 and will be updated in 2026 to include issues 12.3 and 13.1.
18. The BP website has continued to be positively received by users. Several improvement features have been added to the BP 2026 online publication including a new accounts and dashboard for every user of the BP, the ability to provide feedback on every page, a live webchat feature and a new tool for users to sign up for updates as well as simpler processes for purchasing. Further improvements are being developed based on user feedback through extensive customer research.
19. Following the regular public consultation scheduled for new and revised monographs, four three-month consultation periods were held during 2025. This continued to provide users with the opportunity to contribute to the monograph development and revision process, helping to ensure that published monographs are relevant and robust.

Prices and Availability

20. Details of the prices and availability of the above-mentioned publications are shown in **Appendix I**.
21. In addition, users can purchase access to a maximum of three individual BP monographs, together with the necessary supporting information including the Introduction, General Notices, Appendices and Supplementary Chapters.

Future Publications

22. By the end of 2025 work was progressing on the preparation of the next editions of the BP and BP (Vet). These will be published during 2026 and will have an effective date of 1st January 2027.

Biological Medicines

23. In 2025 the focus for Biological medicines continued to be the development of guidance that support the characterisation and robust analysis of cell and gene therapy products (ATMPs) as well as to maintain quality standard monographs for biological products.
24. The EAG ATMP continued to develop non-mandatory guidance documents that support quality and innovation in these medicines. Revised guidance and best practice for the determination of genomic titre and vector copy number was published as well as new guidance on replication competent virus (RCV) testing in September. These guidance documents were made freely available on the British Pharmacopoeia website www.pharmacopoeia.com/guidance/atmp. The published guidance is developed and approved by the BP, as part of the MHRA, in partnership with experts from the cell and gene therapy community including representatives from industry, the NHS and academia.
25. In December, two new draft guidance were made available for public consultation that build on existing BP guidance for the characterisation recombinant adenoassociated virus gene therapy products; Part 2, Characterisation of the Capsid Particle Population in rAAV Products: Determination of Vector Genome Identity, Integrity and Encapsidated DNA Impurities and Part 3, Characterisation of the Capsid Particle Population in rAAV Products: Capsid Protein Characterisation.
26. The importance of stakeholder contributions and systems-wide approaches is recognised, and the ATMP EAG includes representatives from the NHS, academia, industry, and the UK Catapult network. In addition, a close working relationship between the MHRA and the Cell and Gene Therapy Catapult continues to be maintained, and support the work and continued staff development in both organisations. The EAG continues to focus on horizon scanning opportunities for this sector, identifying new topics for BP guidance development of value to the ATMP community.

Unlicensed Medicines

27. Monographs that have been developed to cover unlicensed formulations are identified as such in the BP. These monographs provide legally enforceable standards for unlicensed formulations which may be widely used or are required for certain patient populations. The BP is also continuing to develop further guidance for prescribers, manufacturers and suppliers of unlicensed medicines which will be included in future publications.

28. Two new monographs for unlicensed formulations, Diltiazem Cream and Lansoprazole Oral Suspension, were published in the BP 2026. Development and improvement of monographs for unlicensed formulations continues, often as part of a series of family monographs alongside those for licensed products containing the same active ingredient. This initiative will make the most efficient use of Laboratory resources and will provide assurance that the methods for the unlicensed formulations are suitable.

Herbal and Complementary Medicines

29. Following the publication of new extract monographs for Green Tea Dry Extract and Decaffeinated Green Tea Extract in the BP 2025 edition, work continued throughout the year to progress further extract monographs, with a draft monograph for Juniper Tincture being published for public consultation during 2025 and laboratory work continuing on methods for Chinese Goldthread and Wormwood extracts.
30. In parallel, work to maintain and update the existing monographs for herbal medicines which are still used and would benefit from modernisation continued, and revised monographs for Capsicum Tincture, Indian Sandalwood Oil, Podophyllum Resin, Compound Podophyllum Paint, Senna Tablets and Squill were published in the BP 2026. The Appendix and Supplementary Chapter on DNA Based Identification Techniques were also updated.
31. Several outdated and superseded monographs (Senna Liquid Extract, Standardised Senna Granules and Sesame Seed), have also been omitted from the BP 2026, to ensure that the monographs included reflect marketed products.

Nomenclature

32. The BP continued to provide advice and comments to the World Health Organization (WHO) Committee on International Non-proprietary Names (INN). Recommended INN (rINN) for products licensed in the UK are formally adopted as BANs when they are first included in licensed medicines. UK Experts provided input into two INN Consultations during the year and contributed to the evaluation of INN requests and the development of WHO policies on drug nomenclature. Two rINN Lists (132 and 133) were published by WHO during the year.
33. The BP Secretariat is also responsible for advising the MHRA on the acceptability of proposed invented names for medicines in the UK. BP staff also continue to provide advice to manufacturers on the acceptability of invented names and remain the experts on the acceptability of invented names within the MHRA.

Sustainability

34. Since the publication of the first BP Sustainability Information Pack in March 2024, this has been downloaded by over 100 BP users. This pack aims to address environmental impacts associated with quality control testing, primarily in laboratory settings, and includes several case studies from stakeholders to support the adoption of greener practices. Work to update the Sustainability Information Pack continued during 2025, and an updated information pack, containing several new case studies, was published in August 2025.
35. Trials in the BP laboratory to reduce solvent usage during quality control testing through method adjustments continued during 2025. These adjustments include solvent recirculation, avoiding solvent pre-mixing and scaling chromatographic methods, demonstrating significant reductions in solvent usage without compromising test results.

Liaison with Other UK Organisations

36. The BP and Veterinary Medicines Directorate (VMD), an executive agency of the Department for Environment, Food and Rural Affairs, continue to collaborate closely on the development of monographs for veterinary medicines through representation from the VMD on Expert Advisory Groups.

The MHRA is a member of the Pharmaceuticals in the Environment (PiE) a collaboration of UK regulators including the VMD, Environment Agency, Health and Safety Executive, and devolved nations equivalents. This group aims to address the prevalence of certain animal and human medicines in the water tables of the UK through monitoring, regulatory action and raising awareness. In 2025 the Group focussed on the prevalence of 2 active substances used in flea and tick treatments for domestic pets, fipronil and imidacloprid, and input into the VMD nationwide Pet Survey to determine owner's awareness of, and adherence to, product usage and disposal instructions. The knowledge gained is also pertinent to addressing anti-microbial resistance (AMR) and will inform future evaluation of human medicines in the environment. The BP is supporting the MHRA Partnerships group in this task.

37. Seven Centres of Excellence in Regulatory Science and Innovation (CERSIs) were introduced in 2025 following expressions of interest in 2024. Jointly funded by the MHRA, Office for Life Sciences and Medical Research Council, and administrated by Innovate UK, the winning CERSI bids strive to support UK manufacturing with a focus on efficient use and scaling of new technologies and approaches. The CERSIs also provide the MHRA with educational materials and access/insights into emerging technologies, which in turn accelerate the development of new regulatory practices and policies. BP

staff are supporting these programs to varying degrees as those new approaches evolve into new best practices and standards.

Laboratory

- 38. The Laboratory has continued to support the work of the BPC and the wider MHRA remit relating to public health throughout 2025.
- 39. During the year laboratory work on thirteen new and revised BP monographs was undertaken for inclusion in future publications. The Laboratory also provided data to support several regulatory investigations during the year.
- 40. The Laboratory relocated, from Teddington to Guildford, in June 2025. This involved a significant amount of planning and logistics to ensure a successfully move, with the least possible impact on laboratory output and service to our customers.

BP Reference Materials

- 41. Twelve new BPCRS were established to support the BP and BP (Vet) publications, forty-nine were replaced and one hundred and ninety were re-tested to ascertain their continued stability.
- 42. Eight of the new BPCRS that were introduced into the BP 2026 and BP (Vet) 2026 were made available by July 2025 in advance of the publication in August 2025, with the remaining four materials made available by November 2025. Making the materials available as early as possible ensures that users are ready to comply with the new and revised monographs before they come into force.
- 43. The demand for these reference materials remained high throughout the year. A total of 39,060 vials were sold within the UK and to countries worldwide, representing an increase of approximately 0.7% compared to the previous year.

European Pharmacopoeia

- 44. Issues 12.1 and 12.2 of the European Pharmacopoeia were published in July 2025 and October 2025 respectively. Issue 12.1 would come into effect on 1 January 2026 and

issue 12.2 will come into effect on 1 April 2026. Issue 12.3 was published in January 2026 and will come into effect on 1 July 2026. The text of these publications was included in the online BP in advance of their effective date and will be published in the next editions of the BP and BP (Vet) as appropriate.

45. The UK continued to play a highly active role in supporting the work of the EPC and its Groups of Experts and Working Parties, providing experts to groups that are most relevant to the UK market. Members of the UK delegation represented the BPC at meetings of the EPC, providing valuable input to the work of that Commission.
46. The Laboratory provides technical support for the work of the EPC, providing technical data to support the elaboration of new monographs and the revision of existing monographs.
47. A list of the current membership of the United Kingdom delegation, and the names of the UK members of Groups of Experts and Working Parties during 2025, is included in Appendix II.

International Liaison and Collaboration

48. Liaison was maintained on a wide range of topics relating to pharmacopoeial matters and nomenclature with various international organisations and bodies including the World Health Organization (WHO) and the United States Pharmacopeia (USP). The BP Scientific Director was a virtual delegate (and voting member) to the USP Convention held in May 2025. The convention occurs every 5 years and sets the strategic direction for the organisation. The UK contributed to the discussions and supported the seven resolutions that were passed, which can be found on the USP website.
49. The Scientific Director attended the fifteenth International Meeting of World Pharmacopoeias, hosted in New Delhi by the Indian Pharmacopoeia Commission (IPC). BP Secretariat staff led a project to create a Terms of Reference document with the goal to improve governance and focus, and to support the India/US-led project on climate-friendly principles. Both projects were progressed with initial agreements made at the February meeting, and will be augmented in 2026, the former being led by the European Pharmacopoeia.
50. Throughout the year BP Secretariat staff provided feedback to WHO on draft monographs for the International Pharmacopoeia, which was greatly appreciated. Many of the standards included in the International Pharmacopoeia, and the policies employed, are consistent with those in the BP.
51. The BP attended the 59th WHO Expert Committee meeting on Specifications for Pharmaceutical Preparations in October during which monographs and reference materials for the International Pharmacopoeia were discussed.

52. With the USP, the BP co-hosted an Environmental Sustainability Summit in London in November engaging a varied cross section of stakeholders to identify obstacles and opportunities to improve the efficiency and sustainable footprint of quality standards across the pharmaceutical lifecycle and across borders. The outputs will form part of the prioritisation process for 2026 activities.
53. BP staff attended the 80th and 81st WHO Consultations on INN in March and October. This regular INN committee discussed and agreed a significant number of names for new chemical and biological substances at both meetings.

Acknowledgements

54. The BPC wishes to express its gratitude to all EAG, Panel and WP members for their invaluable contribution to the continuing improvement of standards in the British Pharmacopoeia (BP). It also thanks all UK expert representatives to the European Pharmacopoeia Expert Groups and Working Parties, as well as members of the United Kingdom delegation to the European Pharmacopoeia Commission (EPC), for the time, attention and expertise they have generously contributed both to the work of the BPC and to the UK delegation to the EPC. In particular, the BPC acknowledges the significant contributions of those members who have now retired from its EAGs, Panels of Experts and Working Parties.
55. The BPC also wishes to record its immense gratitude to the staff of the BP and Laboratory Services Group of the MHRA. Significant input to the work of the BPC continued to be received from members of staff from the following Groups of the MHRA: Healthcare, Quality & Access; Scientific Research & Innovation; Communications and Engagement. Significant input has also been received from the BP and MHRA Laboratories, from the Department of Health and Social Care, from the Cell and Gene Therapy Catapult and from the Veterinary Medicines Directorate.
56. The BPC wishes to acknowledge the advice of the publishing team at The Stationery Office (TSO) in the production of the BP 2026, the BP (Vet) 2026 and BAN 2026.

APPENDIX I

BRITISH PHARMACOPOEIA COMMISSION PUBLICATIONS DURING 2025

Publications may be purchased from TSO Customer Service Centre, or from the British Pharmacopoeia's pharmacopoeia.com website.

British Pharmacopoeia 2026 package

Consisting of: -

British Pharmacopoeia 2026

British Pharmacopoeia (Veterinary) 2026

New pricing structure to reflect increasing operational costs since the last price review in 2013, in particular for print production.

APPENDIX II

Membership of the British Pharmacopoeia Commission

Post	Name and title	Affiliations
Chair	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Vice Chair	Mr Robert Lowe BPharm FRPharmS	Former hospital pharmacist and Quality Assurance Specialist Lead Pharmacist for Specialist Pharmacy Services (NHS England)
Member	Dr Emre Amirak BSc MBBS MRCS	Chief Medical Officer, Proveca Limited; Chief Medical Officer & Chief Scientific Officer, Vionelix Pharmaceuticals
Member	Dr Edward Bush BSc PhD	Principal Scientist – Pharmacopoeial Specialist, Chemical Development, AstraZeneca
Member	Dr Ka Lung Chan MEng PhD DIC MRSC	Reader in Pharmaceutical Molecular Spectroscopy, Kings College London, Head of the Medicine Development Department
Member	Mr Carlo Emanuele Giartosio MSc	Former Regulatory Coordination & Scientific Support Manager, Merck Serono
Lay Member	Mrs Hayley Hall BA	Public representative on NIHR's Strategy and Engagement Board
Member	Dr Janet Halliday BSc PhD FRPharmS	Former Associate Vice President, Ferring Controlled Therapeutics
Member	Dr Vikas Jaitely PhD, MR Pharm S, MTOPRA	Head, GRA Digital Health and Devices, Global Regulatory Affairs - R&D Quality and Safety, Merck KgAA
Member	Mr Sean Jones BSc MSc MRPharmS	Former Expert Quality Assessor, MHRA; Former Trust Quality Controller, Guy's and St. Thomas' NHS Foundation Trust
Member	Dr Oisin Kavanagh MPharm PhD SFHEA FRPharmS	Senior Lecturer in Pharmaceutics, Newcastle University
Member	Professor Majella Lane BSc PhD FAPS	Professor of Pharmaceutics and Director of the UCL Drug Delivery Group
Member	Dr Paul Marshall BPharm PhD MRPharmS MAPS FTOPRA	Director of CMC Regulatory Affairs, Otsuka Pharmaceuticals
Lay Member	Ms Claire Nicholson BA Dipl.-Betriebswirt MBA	Lay/Consumer representative and Deputy Chair of the Food Standards Agency Science Council
Member	Professor Yvonne Perrie BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences,

		University of Strathclyde, Glasgow. Scotland
Member	Mr James Rickard MPharm	Chief Scientific Officer, Richmond Research Institute; Visiting Senior Lecturer, Kings College, London
Member	Professor Monique Simmonds¹ OBE JP BSc PhD FLS FBS FRES FWIF	Deputy Director of Science, Royal Botanic Gardens, Kew

Membership of the Anti-Infective Medicines Expert Advisory Group (AIM EAG)

Post	Name and title	Affiliations
Chair	Dr Rodney Horder BPharm, PhD, MRPharmsS	Former Vice President, Strategic Regulatory Affairs, Europe, Abbott Laboratories
Vice Chair	Dr Graham Cook PhD	Consultant
Member	Mr Faraat Ali BPharm MRPharm PGDDRA PGDM	Research Scientist, Department of Analytical Chemistry, Charles University, Czech Republic
Member	Mr Greg Blake MRSC, CChem	Regional Quality Director GSK
Member	Mr Eamon Flahive B.Sc, HDAS (Ap.Sci), PDRA	Former Director and Head of Regulatory Affairs, Elanco Animal Health
Member	Dr Vikas Jaitely PhD, MR Pharm S, MTOPRA	Head, GRA Digital Health and Devices, Global Regulatory Affairs - R&D Quality and Safety, Merck KgAA
Member	Mr Sean Jones BSc MSc MRPharmS	Former Expert Quality Assessor, MHRA; Former Trust Quality Controller, Guy's and St. Thomas' NHS Foundation Trust
Member	Professor John Miller² PhD	Retired. Professor, Strathclyde University
Member	Mr Ian Williams BSc, MSc	Former Quality Director Sumitomo Pharmaceuticals Europe Ltd

¹ Stepped down 31/12/2025

² Retired 22/09/25

Membership of the Biological and Biotechnological Products Expert Advisory Group (BIO EAG)

Post	Name and title	Affiliations (if applicable)
Chair	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Vice Chair	Dr Emre Amirak BSc MBBS MRCS	Chief Medical Officer, Proveca Limited; Chief Medical Officer & Chief Scientific Officer, Vionelix Pharmaceuticals
Member	Mr Simeon Gill BPharm MSc AMIChemE	Director, CMC Regulatory Affairs, AstraZeneca
Member	Dr Lyn Healy BSc MSc PhD CSci FRSB	Principal Laboratory Research Scientist Human Embryo and Stem Cell Unit, The Francis Crick Institute
Member	Dr Ahmed Keed BSc	QC Compliance Senior Specialist, Polpharma Biologics Company, Gdansk Site, Poland
Member	Dr Garry Lavery PhD MPharm FHEA MRSC	Reader in Pharmaceutical Sciences, School of Pharmacy, Queen's University Belfast
Member	Dr Brij Patel BPharm MRPharmS PhD	RegExcel Consulting Ltd.
Member	Mr Lionel Randon MSc	Head of GRA CMC Regulatory Intelligence, Merck KGaA, Switzerland
Member	Dr Robin Thorpe PhD FRCPATH	Fellow of the Royal College of Pathologists Former Head of Biotherapeutics Group, National Institute for Biological Standards and Control
Member	Mr Paolo Tozzi MSc	Former Global QC Director Pharmacopoeia Affairs and External Engagement, Moderna Inc
Member	Dr Lincoln Tsang BPharm LLB PhD FRSC FRCPharm FRSB FRSA FRSM Solicitor	Partner and Head of Life Sciences Practice, Ropes & Gray LLP
Member	Dr Paul Varley PhD	Senior Vice President Development, Alchemab Therapeutics

Membership of the Herbal and Complementary Medicines Expert Advisory Group (HCM EAG)

Post	Name and title	Affiliations
Chair	Professor Monique Simmonds OBE JP BSc PhD FLS FBS FRES FWIF	Deputy Director of Science, Royal Botanic Gardens, Kew
Vice Chair	Dr Dick Middleton PhD, MPhC	Director, British Herbal Medicine Association
Member	Mr Paul Anderson BSc(Hons) CBiol MRSB	Head of Compliance, G R Lane Health Products Ltd.
Member	Dr Anthony Booker MSc, PhD, MRSC, FLS	Reader in Ethnopharmacology, University of Westminster Honorary Lecturer UCL School of Pharmacy Associate Editor, Frontiers in Ethnopharmacology Fellow of The Linnean Society
Member	Dr Christopher Etheridge PhD MRSC MCPP CChem DoIC ARCS BSc (Hons) Chem BSc (Hons) Phyto	Chair of the British Herbal Medicine Association, President of the European Herbal and Traditional Medicine Association, Director and Council Member of the College of Practitioners of Phytotherapy, Director of the European Scientific Cooperative on Phytotherapy, Member of the Royal Society of Chemistry, Chartered Chemist, Medical Herbalist.
Member	Mr Barry Moore BSc MSc	Regulatory Affairs Consultant – Herbs, Bath
Lay Member	Ms Claire Nicholson ³ BA Dipl.-Betriebswirt MBA	Lay/Consumer representative and Deputy Chair of the Food Standards Agency Science Council
Member	Dr Eike Reich PhD	Retired.
Member	Professor Adrian Slater BSc MSc PhD	Emeritus Professor, Faculty of Health and Life Sciences, De Montfort University
Member	Professor Katja Strohfeldt PhD, PGCAP, MRSC, PFHEA	Professor in Pharmaceutical Chemistry and Education (School of Pharmacy, University of Reading), Associate Pro-Vice Chancellor, Vice-Chancellor's Office, University of Reading
Member	Dr Ruben Thanacoody PGCertEd MD FRCP FRCP(Edin)	Consultant Physician, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust Honorary Clinical Senior Lecturer in Clinical Pharmacology, Newcastle University Honorary Consultant Clinical Toxicologist, UK Health Security Agency

³ Appointed 30/06/2025

		Director National Poisons Information Service (Newcastle unit)
Member	Mr Clive Welham MRSC	Technical Manager, Ransom Naturals Ltd.
Member	Professor Elizabeth Williamson BSc(Pharm) PhD	Emeritus Professor of Pharmacy, The School of Pharmacy, University of Reading
Member	Dr Kaicun Zhao MB MM PhD	Retired. Former Programme Leader in Chinese Herbal Medicine Department of Mental Health, Social Work and Integrative Medicine School of Health, Social Care & Education, Middlesex University London

Membership of the Medicinal Chemicals Expert Advisory Group (MC1 EAG)

Post	Name and title	Affiliations
Chair	Dr Paul Marshall BPharm PhD MRPharmS MAPS FTOPRA	Director of CMC Regulatory Affairs, Otsuka Pharmaceuticals
Vice Chair	Dr Edward Bush BSc PhD	Principal Scientist – Pharmacopoeial Specialist, Chemical Development, AstraZeneca
Member	Dr Varada Bapat BPharm MPharm PhD	Head of Formulation, IP and Regulatory Step Bio Science, Bengaluru, Karnataka, India
Member	Dr John Berridge BSc PhD FRSC	Independent Pharmaceutical Consultant
Member	Mr Seamus Boland BSc	Analytical Science & Technology Specialist, SGS International Service Laboratories
Member	Professor Donald Cairns BSc (Hons), PhD FRPharmS FRSC.	Professor Emeritus, School of Pharmacy and Life Sciences, Robert Gordon University
Member	Mr Adrian Caws GRSC PGDip	Retired
Member	Mr Paul Fleming BPharm MSc MRPharmS	Technical Director for Medicines UK
Member	Dr John Lough PhD	Programme Leader, MSc Drug Discovery and Development, University of Sunderland
Member	Mr Dave Malpas BSc MRSC CChem.	Pharmaceutical Consultant
Member	Mr Steven Nolan MChem, MRSC	QP Consultant/Director, United QP Consulting Ltd

Membership of the Medicinal Chemicals Expert Advisory Group (MC2 EAG)

Post	Name and title	Affiliations
Chair	Dr Graham Cook PhD	Consultant
Vice Chair	Mr Chris Goddard BSc DIS CSci CChem FRSC	Analytical Consultant
Vice Chair	Mr James Rickard MPharm	Chief Scientific Officer, Richmond Research Institute; Visiting Senior Lecturer, Kings College, London
Member	Mr Mohamed Abdelhamid Ali BPharm TQM	QC/R&D Head, Sunny Pharmaceutical
Member	Professor James Birchall B.Pharm.(Hons), Ph.D., FHEA	Deputy Head of School School of Pharmacy and Pharmaceutical Sciences College of Biomedical and Life Sciences Cardiff University
Member	Dr Ka Lung Andrew Chan ⁴ , MEng PhD DIC MRSC	Reader in Pharmaceutical Molecular Spectroscopy, Kings College London, Head of the Medicine Development Department
Member	Mr James Cowie BSc	Retired, Formerly Analytical Consultant, Novartis Pharma AG, Basel, Switzerland, Formerly Regulatory Facilitator and Lead, Analytical Science and Technology Team, Novartis Grimsby Ltd
Member	Dr Karen Foster MSc FRSC C.Chem	Group Scientist Quality Expert, PHC Global Product Stewardship. Procter & Gamble Technical Centres
Member	Mr Elliot Hook MChem	QC Analytical Standards Senior Lead, GSK
Member	Professor John Miller ⁵ PhD	Retired. Professor, Strathclyde University
Member	Mr Shekhar Natarajan BSc MSc FRSC FTOPRA	Vice President - Regulatory Affairs, Dyne Therapeutics
Member	Dr Andrea Ruggiero PhD	Director - GRA CMC Regulatory Intelligence, Merck KGaA
Member	Dr Zena Smith BSc, PhD	Senior Director, Regulatory CMC Jazz Pharmaceuticals
Corresponding Member	Professor Marius Brits B.Pharm, MSc (Pharmaceutics), Ph.D. (Pharmaceutics)	Associate - Professor, North-West University, School of Pharmacy, Potchefstroom, South Africa

⁴ Appointed 13/05/2025

⁵ Retired 22/09/2025

Membership of the Medicinal Chemicals Expert Advisory Group (MC3 EAG)

Post	Name and title	Affiliations
Interim Chair	Mr Ian Williams BSc, MSc	Former Quality Director Sumitomo Pharmaceuticals Europe Ltd.
Co-vice Chair	Mr Carlo Emanuele Giartosio MSc	Former Regulatory Coordination & Scientific Support Manager, Merck Serono
Co-vice Chair	Mr Chris Goddard BSc DIS CSci CChem FRSC	Analytical Consultant
Member	Mr Martin Coxon MChem ARCS	Head of Quality and Analytical Services
Member	Dr Karen Foster MSc FRSC C.Chem	Group Scientist Quality Expert, PHC Global Product Stewardship. Procter & Gamble Technical Centres
Member	Mr Phil Hampshire BSc Hons	QC Analytical Support Senior Team Leader, Accord Healthcare.
Member	Professor Majella Lane BSc PhD FAPS	Professor of Pharmaceutics and Director of the UCL Drug Delivery Group
Member	Mr Jigar P. Mehta M.Sc.	Deputy General Manager, (Subject Matter Expert Analytical/Quality), Zydus Lifesciences Ltd Member of Stakeholder Engagement Planning Committee in US Pharmacopoeia. Reviewer for monograph and guidance in International Pharmacopoeia (WHO).
Member	Ms Desireen Nader Obaid BSc, MSc	Scientific Affairs Manager, Joswe Medical Pharmaceuticals
Member	Professor Yvonne Perrie ⁶ BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
Member	Mr Ron Torano BSc PhD MRSC	Former Process Owner, Quality Regulatory Intelligence, GlaxoSmithKline
Member	Mr Chris Turville MSci MRSC MRQA	Raw Materials Team Leader, Wrafton Laboratories Ltd (trading as Perrigo)

⁶ Appointed 03/03/2025

Membership of the Pharmacy and Nomenclature Expert Advisory Group (PCN EAG)

Post	Name and title	Affiliations
Chair	Dr Jeff Aronson MA, DPhil, MBChB, FRCP, HonFFPM, HonFBPhS	Hon Consultant Physician and Clinical Pharmacologist, Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences
Vice Chair	Mr Robert Lowe BPharm FRPharmS	Former hospital pharmacist and Quality Assurance Specialist Lead Pharmacist for Specialist Pharmacy Services (NHS England)
Member	Dr Adam Brelsford ⁷ MPharm PhD	Senior Clinical Writer – Pharmaceutical Press, Royal Pharmaceutical Society
Member	Dr David Elder PhD, FRSC, CChem	Independent CMC consultant
Member	Dr Rodney Horder BPharm, PhD, MRPharmsS	Former Vice President, Strategic Regulatory Affairs, Europe, Abbott Laboratories
Member	Dr Oisin Kavanagh MPharm PhD SFHEA FRPharmS	Senior Lecturer in Pharmaceutics, Newcastle University
Member	Mr John McGuire BSc MSc	Regulatory Affairs Director
Member	Dr Gerard P Moss BSc, PhD ARCS	Emeritus Senior Lecturer in Organic Chemistry, Queen Mary University of London
Member	Professor Kevin Taylor BPharm, PhD, FRPharmS	Emeritus Professor, University College London
Member	Dr Robin Thorpe PhD FRCPPath	Fellow of the Royal College of Pathologists Former Head of Biotherapeutics Group, National Institute for Biological Standards and Control

⁷ Stepped down 26/09/2025

Membership of the Unlicensed Medicines Expert Advisory Group (ULM EAG)

Post	Name and title	Affiliations
Chair	Mr Robert Lowe BPharm FRPharmS	Former hospital pharmacist and Quality Assurance Specialist Lead Pharmacist for Specialist Pharmacy Services (NHS England)
Vice Chair	Dr Julian Smith PhD MRPharmS	Director at JCS Pharma Consulting Ltd
Member	Mr Alex Bosley BPharm MRPharmS	Lead Qualified Person & Pharmacist, Torbay Pharmaceuticals Ltd
Member	Mr Wayne Goddard MSc	Education & Training Lead – Pharmacy & Quality Control North Tees & Hartlepool NHS Foundation Trust
Member	Dr Janet Halliday BSc PhD FRPharmS	Former Associate Vice President, Ferring Controlled Therapeutics
Member	Ms Sarah Hartley BSc (Hons)	Manager Analytical R&D Rosemont Pharmaceuticals Ltd
Member	Mr Joaquim Ramada-Magalhes BSc, MSc, CChem, CSci, MRSC	Associate Director, Global Quality Compliance, Lonza Senior QA Manager (Consultant), St Barts NHS Trust – Nuclear Medicine & Radiopharmacy
Member	Mr Andrew Sully BPharm MRPharmS	Principal Pharmacist Quality Control & Qualified Person Cardiff and Vale University Health Board St. Marys Pharmaceutical Unit (SMPU)
Member	Mr Adam Walker MPharm MRPharmS	Head of Development and Innovation, North East and North Cumbria Aseptic Medicines Production Hub, Qualified Person at Newcastle Advanced Therapies and Newcastle Specials

Membership of the Panel of Experts for Blood Products (BLP Panel)

Post	Name and title	Affiliations
Chair	Dr Paul Varley PhD	Senior Vice President Development, Alchemab Therapeutics
Member	Mr James Rickard MPharm	Chief Scientific Officer, Richmond Research Institute; Visiting Senior Lecturer, Kings' College, London

Membership of the Panel of Experts for Excipients (CX Panel)

Post	Name and title	Affiliations
Chair	Dr Paul Marshall BPharm PhD MRPharmS MAPS FTOPRA	Director of CMC Regulatory Affairs, Otsuka Pharmaceuticals
Member	Professor Hannah Batchelor BSc PhD	Professor of Pharmaceutics and Biopharmaceutics, Strathclyde Institute of Pharmaceutical and Biomedical Sciences, University of Strathclyde
Member	Dr Richard Cawthorne BSc PhD CChem MRSC	Research and Technology Fellow, Croda Europe
Member	Dr Oisin Kavanagh ⁸ MPharm PhD SFHEA FRPharmS	Senior Lecturer in Pharmaceutics, Newcastle University
Member	Mr Chris Turville MSci MRSC MRQA	Raw Materials Team Leader, Wrafton Laboratories Ltd (trading as Perrigo)

Membership of the Panel of Experts for Inorganic and General Chemicals (IGC Panel)

Post	Name and title	Affiliations
Chair	Mr Chris Goddard BSc DIS CSci CChem FRSC	Analytical Consultant
Member	Mr Seamus Boland BSc	Analytical Science & Technology Specialist. SGS International Service Laboratories.
Member	Mr Peter Henrys BSc	QRA Technical Manager, BOC Healthcare
Member	Professor Majella Lane BSc PhD FAPS	Professor of Pharmaceutics and Director of the UCL Drug Delivery Group

⁸ Stepped down 2025

Membership of the Panel of Experts for Microbiology (MIC Panel)

Post	Name and title	Affiliations
Chair	Dr Vikas Jaitely BPharm MPharm PhD MRPharmS GPhC MTOPRA	Head, GRA Digital Health and Devices, Global Regulatory Affairs - R&D Quality and Safety, Merck KgAA
Member	Mrs Miriam Guest PhD	Executive Director and Scientific Advisor, Global Microbial Solutions, Charles River Laboratories
Member	Dr Carol Iversen BSc (Hons) PhD CBiol MRSB MISTR	Associate Scientific Director, Global Development Services, BioReliance, Merck KGaA
Member	Dr Joao Inacio Silva PhD FHEA	Principal Lecturer in Pharmaceutical Microbiology, School of Applied Sciences, University of Brighton; Associate Subject Lead for Pharmacy, School of Applied Sciences, University of Brighton

Membership of the Panel of Experts for Radioactive Materials (RAD Panel)

Post	Name and title	Affiliations
Chair	Dr Paul Marshall BPharm PhD MRPharmS MAPS FTOPRA	Director of CMC Regulatory Affairs, Otsuka Pharmaceuticals
Member	Dr Istvan Boros ⁺ , MSc, PhD, GMP PQS	QA Senior Manager, Qualified Person, Jazz Pharmaceuticals
Member	Dr Margaret Cooper ⁺	Operations Manager, Positron Emitting Radiopharmaceutical Laboratory, King's College London; Director, Cooper Radioisotope Solutions Ltd.
Member	Dr Rebekka Hueting MChem DPhil MRSC	Radiopharmaceutical Unit Lead, Wales Research and Diagnostic PET Imaging Centre, Cardiff University
Member	Dr Roger Pickett B.Pharm, PhD	Retired

⁺ Appointed 06/01/2025

Membership of the Panel of Experts for Veterinary Medicines (VET Panel)

Post	Name and title	Affiliations
Chair	Professor Elizabeth Williamson BSc(Pharm) PhD	Emeritus Professor of Pharmacy, The School of Pharmacy, University of Reading
Member	Mr Andrew Cairns FRPharmS	Managing Director, Murray Farmcare Ltd. Industry liaison
Member	Dr Sarah Cockbill PhD, BPharm, MPharm, LL.M, DAgVetPharm, FRPharmS, FVPA	Honorary Lecturer Cardiff School of Pharmacy and Pharmaceutical Services Cardiff University
Member	Mr Eamon Flahive B.Sc, HDAS (Ap.Sci), PDRA	Former Director and Head of Regulatory Affairs, Elanco Animal Health

Membership of the Panel of Experts for Veterinary Immunological Products (VIP Panel)

Post	Name and title	Affiliations
Chair	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Member	Dr Martin Ilott BVSc PhD MRCVS	Regulatory Consultant
Member	Dr Catrina Stirling BSc (Hon) PhD	Director Regulatory Affairs, Zoetis
Member	Dr Ralph Woodland BSc PhD	Former Senior Assessor in Biologicals Assessment Team, Veterinary Medicines Directorate

Membership of the Analytical Quality by Design Working Party (AQbD WP)

Post	Name and title	Affiliations
Chair	Dr Graham Cook PhD	Consultant
Member	Dr Stephen L R Ellison FRSC CChem	Chief Metrologist & Science Fellow, National Measurement Laboratory, LGC Ltd, Guildford
Member	Mr Andrea Gheduzzi ⁺	EMEA Principal LC Market Development Manager, Waters Corporation
Member	Dr Peter Hamilton ⁹ PhD	Head of Product and Process Control, AstraZeneca, UK
Member	Professor Melissa Hanna-Brown PhD	Chair of Analytical Science, School of Chemistry, University College Cork
Member	Mr Patrick Jackson ⁺	Principal Scientist, GSK
Member	Mr Sean Jones BSc MSc MRPharmS	Former Expert Quality Assessor, MHRA; Former Trust Quality Controller, Guy's and St. Thomas' NHS Foundation Trust
Member	Dr Rosario LoBrutto PhD MBA MS	Vice President, Global Technical Operations Ironwood Pharmaceuticals, Boston, USA
Member	Dr John Lough PhD	Programme Leader, MSc Drug Discovery and Development, University of Sunderland
Member	Dr Tina Morris Ph.D.	Executive Director, American Association of Pharmaceutical Scientists (AAPS)
Member	Dr Phil Nethercote BSc PhD	Retired
Member	Dr . Mustafa A. Zaman BPharm (Hons) PhD MRPharmS	Principal Consultant, Granzer Regulatory Consulting and Services GmbH; Visiting Senior Lecturer, King's College, London
Corresponding Member	Dr Kimber Barnett PhD	Former Research Fellow, Pfizer, Groton, USA
Corresponding Member	Mr Brent Harrington MSc	Senior Director and Drug Product Statistics Lead, Pfizer Research and Development, PSSM Data Sciences, Groton, CT

⁺ Appointed 03/03/2025

⁹ Resigned 10/01/2025

Membership of Advanced Therapy Medicinal Products Working Party (ATMP EAG)

(incorporating the sub-groups on (i) Flow Cytometry, (ii) Vector Copy Number, (iii) Empty Capsids for AAV Products and (iv) T Cell and NK Cell Characterisation Assays)

Post	Name and title	Affiliations
Chair	Dr Jacqueline Barry PhD	Chief Clinical Officer, Cell and Gene Therapy Catapult
Member	Dr Clare Blue Ph.D	Senior CMC Translation Consultant, eXmoor Pharma Concepts Ltd.
Member	Dr Meg Byrne ⁺	Former Associate Director – Cell Therapy Engineering, bit.bio
Member	Dr Paul Carter BSc	Senior Director MSAT, Quell Therapeutics
Member	Dr David Caulfield MD	NHS
Member	Dr Rehma Chandaria	Senior Regulatory Affairs Lead. Cell and Gene Therapy Catapult
Member	Dr Leanne Di Rollo BSc PhD	Associate Director, Regulatory Affairs, IQVIA
Member	Dr Paul Getty BSc (Hons), PhD	Senior Technical Specialist, Pharmaron Biologics (UK) Ltd.
Member	Dr Kimberly Gilmour Ph.D., FRCPATH	Chief of Laboratory Medicine, Consultant Clinical Scientist, Clinical Lead Immunology and Director of Cell Therapy Camelia Botnar Laboratories Great Ormond Street Hospital for Children NHS Foundation Trust
Member	Dr Alan Griffith PhD	Head of Global Operations, VectorBuilder
Member	Dr Garth Hamilton ⁺	Ex Adaptimmune employee. Business development manager, CancerTools
Member	Dr Jennifer Harbottle ⁺	Associate Director, Cell Therapy Nonclinical Safety, AstraZeneca
Member	Dr Lyn Healy BSc MSc PhD CSci FRSB	Principal Laboratory Research Scientist Human Embryo and Stem Cell Unit, The Francis Crick Institute
Member	Dr Ishtiaq Khaliq BSc, MSc, PhD	Lead Gene Therapy Molecular Biology Sciences. GT Analytical Sciences, UCB, Brain l'Alleud, Belgium
Member	Dr Mark Lowdell PhD FRCPATH FRSB	Professor of Cell & Tissue Therapy, UCL
Member	Dr Keith McLuckie BSc, PhD	Head of Non-Clinical Cell and Gene Therapy Catapult

⁺ Appointed 30/06/2025

Member	Dr Leonard Pattenden PhD	CEO, CMC Biopharma Ltd, UK
Member	Mr Ian Rees BSc	Regulatory Affairs Consultant, D.I., Rees Ltd
Member	Dr Chaminda Salgado BSc	CMC Innovation Lead, CEPI (Coalition for Epidemic Preparedness and Innovation)
Member	Ms Isobel Searing BSc	Director, Quality Assurance, Replimune
Member	Professor Michael Themis⁺	Group Leader of the Gene Therapy and Genotoxicity Group and CSO of TestAvec Ltd, Brunel University Uxbridge, London UK
Member	Dr Giandomenico Turchiano⁺	Associate director, Cell and Gene therapy safety, AstraZeneca, Cambridge, UK. Honorary team leader, Molecular and Cellular Immunology Section UCL GOS Institute of Child Health, London, UK.
Member	Dr Christian van den Bos PhD	Managing Director, Mares ITX GmbH, Germany
Member	Dr Athea Vichas⁺	Senior Principal Scientist, Bristol Meyers Squibb
Member	Dr Caroline Weydert PharmD PhD	EMEA Sales Specialist Genomics - Biopharma Bio-Rad Laboratories N.V

⁺ Appointed 30/06/2025

Membership of Alternative Approaches for Documentary and Physical Standards for Biotechnological Products Working Party (BIO-DPS WP)

Post	Name and title	Affiliations
Chair	Dr Paul Varley PhD	Senior Vice President Development, Alchemab Therapeutics
Vice Chair	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Member	Dr Laurent Duhau ¹⁰ PhD	Sanofi R&D, Global CMC Development, Global Head of BioAnalytics
Member	Mr Carlo Emanuele Giartosio MSc	Former Regulatory Coordination & Scientific Support Manager, Merck Serono
Member	Dr Friederike Plath PhD	Senior Scientist, Pharmaceutical Technical Development Europe, F. Hoffmann-La Roche Ltd, Switzerland
Member	Dr Alla Polozova PhD	Director, Attribute Sciences, Process Development, Amgen
Member	Dr Ash Ramzan PhD, FTOPRA	Principal Consultant, Woodley Bioreg Ltd.

EUROPEAN PHARMACOPOEIA COMMISSION – Members of the United Kingdom Delegation During 2025

	Name	Affiliations
Main	Dr Anna-Maria Brady BSc PhD	Former Head of Biologicals and Administration, Veterinary Medicines Directorate
Main	Mr Robert Lowe BPharm FRPharmS	Director of Pharmacy Quality Assurance Specialist Services, NHS East of England & Northamptonshire
Main	Mr Stephen Hoare	Head of Standards & Regulatory Governance, Medicines and Healthcare products Regulatory Agency (MHRA)
Alternates	Mr Peter Crowley	Head of BP & Labs, MHRA
Alternates	Mr Stephen Young	Head of BP/Labs Team, MHRA

¹⁰ Stepped down 30/06/2025

DECLARATION OF INTERESTS

British Pharmacopoeia Commission, BPC's Expert Advisory Groups members, Working Parties and Panels of Experts have declared current personal and non-personal interests in the pharmaceutical industry as follows:

Member	Committee	Interest Type	Company / Organisation / Sponsor	Nature of Interest	Current	Additional Information
Adam Brelsford	PCN EAG	Personal	NIL	N/A	N/A	
Adam Brelsford	PCN EAG	Non-Personal	NIL	N/A	N/A	
Adam Walker	ULM EAG	Personal	NIL	N/A	N/A	
Adam Walker	ULM EAG	Non-Personal	@PharmaQP Ltd.	Contract QP Consultancy, Director	Yes	
Adam Walker	ULM EAG	Non-Personal	Blockchain Pharma Limited	Director	Yes	
Adam Walker	ULM EAG	Non-Personal	W2 Cleanroom Consultants	Director	Yes	
Adam Walker	ULM EAG	Additional				All my external interests are unrelated to activity regarding the BP, they are associated with either consultancy to NHS or non-NHS entities in the field of QA, QP services or general GMP compliance, or linked with the development of the Blockchain Pharma digital pharmaceutical supply chain platform.

Adrian Caws	MC1 EAG	Personal	GSK	Shares	No
Adrian Caws	MC1 EAG	Personal	Haleon	Shares	No
Adrian Caws	MC1 EAG	Non-Personal	NIL	N/A	N/A
Adrian Caws	MC1 EAG	Additional	Immediate family member holds shares in GSK and Haleon. Held Jan to Dec 2025. All Products.		
Adrian Slater	HCM EAG	Personal	Mycorrhizal Systems	Consultancy on DNA barcoding and metagenomics	Yes
Adrian Slater	HCM EAG	Non-Personal	NIL	N/A	N/A
Ahmed Keed	BIO EAG	Personal	POL Pharma Biologics Gdansk site	Salary	Yes
Ahmed Keed	BIO EAG	Non-Personal	NIL	N/A	N/A
Alan Griffith	ATMP EAG	Personal	NIL	N/A	N/A
Alan Griffith	ATMP EAG	Non-Personal	NIL	N/A	N/A
Alex Bosley	ULM EAG	Personal	Torbay Pharmaceuticals Ltd	Salaried QP	Yes
Alex Bosley	ULM EAG	Non-Personal	NIL	N/A	N/A
Alicja Fiedorowicz	ATMP EAG	Personal	Dark Horse Consulting	Shares	Yes
Alicja Fiedorowicz	ATMP EAG	Personal	Pfizer	Shares	Yes

Alicja Fiedorowicz	ATMP EAG	Non-Personal	NIL	N/A	N/A
Alla Polozova	WP BIO-DPS	Personal	Amgen	Salary, Shares	Yes
Alla Polozova	WP BIO-DPS	Non-Personal	NIL	N/A	N/A
Alla Polozova	WP BIO-DPS	Additional			Member of non-profit industry trade groups, including IQ Consortium and IPSE. Participate on a volunteer basis and don't acquire any compensation.
Andrea Gheduzzi	AQbD WP	Personal	NIL	N/A	N/A
Andrea Gheduzzi	AQbD WP	Non-Personal	NIL	N/A	N/A
Andrea Ruggiero	MC2 EAG	Personal	Merck KGaA	Consultancy, Salary	Yes
Andrea Ruggiero	MC2 EAG	Non-Personal	NIL	N/A	
Andrew Cairns	Panel VET	Personal	NIL	N/A	N/A
Andrew Cairns	Panel VET	Non-Personal	NIL	N/A	N/A
Andrew Sully	ULM EAG	Personal	NIL	N/A	N/A
Andrew Sully	ULM EAG	Non-Personal	NIL	N/A	N/A
Anna-Maria Brady	BPC, BIO EAG, WP BIO-DPS, Panel VIP	Personal	GSK	Immediate family member holds shares	Yes

Anna-Maria Brady	BPC, BIO EAG, WP BIO-DPS, Panel VIP	Personal	AstraZeneca	Immediate family member holds shares	Yes
Anna-Maria Brady	BPC, BIO EAG, WP BIO-DPS, Panel VIP	Non-Personal	NIL	N/A	N/A
Anna-Maria Brady	BPC, BIO EAG, WP BIO-DPS, Panel VIP	Additional			I am an editorial board member of the journal Biologicals as well as an occasional reviewer and editor. This is an unpaid position.
Anthony Booker	HCM EAG	Personal	NIL	N/A	N/A
Anthony Booker	HCM EAG	Non-Personal	NIL	N/A	N/A
Archie Lovatt	ATMP EAG	Personal	SGS	Salary	Yes
Archie Lovatt	ATMP EAG	Non-Personal	NIL	N/A	N/A
Ash Ramzan	WP BIO-DPS	Personal	NIL	N/A	N/A
Ash Ramzan	WP BIO-DPS	Non-Personal	NIL	N/A	N/A
Athea Vichas	ATMP EAG	Personal	NIL	N/A	N/A
Athea Vichas	ATMP EAG	Non-Personal	NIL	N/A	N/A
Barry Moore	HCM EAG	Personal	Herbal Reality (herbal medicine advocacy)	Fees – writing scientific content and articles for website	No

Barry Moore	HCM EAG	Personal	Vivian Rolfe (individual start up business)	Consultancy	No
Barry Moore	HCM EAG	Personal	Sebastian Pole (individual start up business)	Consultancy	No
Barry Moore	HCM EAG	Personal	Cambridge Tea Consultancy	Consultancy	No
Barry Moore	HCM EAG	Non- Personal	NIL	N/A	N/A
Beata Surmacz- Cordle	ATMP EAG	Personal	GSK	Shares, Salary	Yes
Beata Surmacz- Cordle	ATMP EAG	Non- Personal	NIL	N/A	N/A
Brent Harrington	AQbD WP	Personal	Pfizer Inc.	Salary	Yes
Brent Harrington	AQbD WP	Non- Personal	NIL	N/A	N/A
Brij Patel	BIO EAG	Personal	Various	Consultancy	Yes
Brij Patel	BIO EAG	Personal	Various legal firms	Consultancy	Yes
Brij Patel	BIO EAG	Personal	Pfizer	Immediate family employment and shares	Yes
Brij Patel	BIO EAG	Non- Personal	NIL	N/A	N/A
Carlo Emanuele Giartosio	BPC, MC3 EAG, BIO- DPS WP	Personal	NIL	N/A	N/A

Carlo Emanuele Giartosio	BPC, MC3 EAG, BIO-DPS WP	Non-Personal	NIL	N/A	N/A
Carol Iverson	Panel MIC	Personal	Bioreliance - a company of Merck KGAA	Salary	Yes
Carol Iverson	Panel MIC	Non-Personal	NIL	N/A	N/A
Caroline Weydert	ATMP EAG	Personal	Bio-Rad Laboratories	Salary and bonus	Yes
Caroline Weydert	ATMP EAG	Personal	Pfizer	Shares	Yes
Caroline Weydert	ATMP EAG	Non-Personal	NIL	N/A	N/A
Catrina Stirling	Panel VIP	Personal	Zoetis	Employment and shares	Yes
Catrina Stirling	Panel VIP	Non-Personal	NIL	N/A	
Catrina Stirling	Panel VIP	Additional			Member of and now chair of the Animal Health Europe Technical and Regulatory committee.
Chaminda Salgado	ATMP EAG	Personal	NIL	N/A	N/A
Chaminda Salgado	ATMP EAG	Non-Personal	NIL	N/A	N/A
Chandrashekar (Shekhar) Natarajan	MC2 EAG	Personal	Dyne Therapeutics	Salaried employee	Yes
Chandrashekar (Shekhar) Natarajan	MC2 EAG	Non-Personal	NIL	N/A	N/A
Chandrashekar (Shekhar) Natarajan	MC2 EAG	Additional			I am currently only employed by dyne therapeutics as a permanent employee and is a full time role. I

am not working for or associated (from financial or personal perspective) with any other industry.					
Christopher Etheridge	HCM EAG	Personal	British Herbal Medicine Association (BHMA)	Chair of the BHMA – receive monthly honorarium.	Yes
Christopher Etheridge	HCM EAG	Personal	UK Tea and Infusions Association (TIA)	Independent consultancy	Yes
Christopher Etheridge	HCM EAG	Non-Personal	NIL	N/A	N/A
Chris Goddard	MC2 EAG, MC3 EAG, Panel IGC	Personal	NIL	N/A	N/A
Chris Goddard	MC2 EAG, MC3 EAG, Panel IGC	Non-Personal	NIL	N/A	N/A
Chris Turville	MC3 EAG, CX Panel	Personal	NIL	N/A	N/A
Chris Turville	MC3 EAG, CX Panel	Non-Personal	NIL	N/A	N/A
Christian van den Bos	ATMP EAG	Personal	Green Phoenix Labs GmbH	MukoCell	Yes
Christian van den Bos	ATMP EAG	Personal	Abbvie	RGX314	Yes
Christian van den Bos	ATMP EAG	Personal	Catalent	IPSC	Yes
Christian van den Bos	ATMP EAG	Non-Personal	NIL	N/A	N/A

Claire Nicholson	BPC, HCM EAG	Personal	NIL	N/A	N/A
Claire Nicholson	BPC, HCM EAG	Non-Personal	NIL	N/A	N/A
Claire Nicholson	BPC, HCM EAG	Additional			I represent consumer interests and am Vice Chair of the Food Standards Agency's Science Council. An Immediate family member is partner at Smedvig Ventures with direct investments in early-stage tech companies, and indirect investments via buy-out funds. None of the companies where the immediate family member takes the lead have any healthcare connection. Two companies in the wider portfolio, not managed by the immediate family member, have links to healthcare but do not supply the NHS or DHSC at present: Antidote, develops software to connect patients to clinical trials. Semble provides practice management software for private medical clinics. Our indirect investments are managed outside the Smedvig group of companies and we have no control over these funds. Another immediate family member is a Medical Doctor, (formerly at Barts NHS healthcare trust) currently undertaking a PhD at Insitut Pasteur in Paris. Their research is about the host and bacterial factors involved in Listeria monocytogenes invasion of the central nervous. Another family member worked as a Band 5 Physiotherapist at Frimley Park Hospital until May 2026
Claire Nicholson	BPC, HCM EAG	Additional			Immediate family member is a Medical Doctor, (formerly at Barts NHS healthcare trust) currently undertaking a PhD at Institut Pasteur in Paris. Their research is about the host and bacterial factors involved in Listeria monocytogenes invasion of the

						central nervous. Another family member works as a Band 5 Physiotherapist at Frimley Park Hospital.
Clare Blue	ATMP EAG	Personal	eXmoor Pharma	Full time employee in role of CMC consultant	Yes	As a consultant to external CGT Companies some of the content defined within the ATMP working group (analytical guidance) may apply to these companies. Additionally, as eXmoor also serves as a CDMO and supporting Clients through process development projects some of the content discussed within the ATMP working group may also apply to these activities.
Clare Blue	ATMP EAG	Non-Personal	NIL	N/A	N/A	
Clive Welham	HCM EAG	Personal	Ransom Naturals Ltd	Salary	Yes	
Clive Welham	HCM EAG	Non-Personal	NIL	N/A	N/A	
Dave Malpas	MC1 EAG	Personal	Sanofi	Shareholder	Yes	
Dave Malpas	MC1 EAG	Personal	Haleon	Shareholder	Yes	
Dave Malpas	MC1 EAG	Personal	Euroapi	Shareholder	Yes	
Dave Malpas	MC1 EAG	Personal	GSK	Shareholder	Yes	
Dave Malpas	MC1 EAG	Non-Personal	NIL	N/A	N/A	
David Caulfield	ATMP EAG	Personal	Caulfield Pharma Consulting	Owner, director, shareholder and employee	Yes	
David Caulfield	ATMP EAG	Personal	Autolus	Consultancy and Shareholder	Yes	

David Caulfield	ATMP EAG	Personal	Pfizer	Consultancy	Yes
David Caulfield	ATMP EAG	Personal	Kings University GVTF	Consultancy	Yes
David Caulfield	ATMP EAG	Personal	Roche	Consultancy	Yes
David Caulfield	ATMP EAG	Non-Personal	NIL	N/A	N/A
David Elder	PCN EAG	Personal	David P Elder Consultancy	Providing paid consultancy for CMC (chemistry, manufacturing & controls) issues	Yes
David Elder	PCN EAG	Personal	GSK	Shares	Yes
David Elder	PCN EAG	Personal	Astra Zeneca	Shares	Yes
David Elder	PCN EAG	Personal	Abbvie	Shares	Yes
David Elder	PCN EAG	Personal	Compass	CMC consultancy	Yes
David Elder	PCN EAG	Personal	Cerebro	CMC consultancy	Yes
David Elder	PCN EAG	Personal	Eliquent	CMC consultancy	Yes
David Elder	PCN EAG	Personal	Otsuka	CMC consultancy	Yes
David Elder	PCN EAG	Non-Personal	NIL	N/A	N/A

David Elder	PCN EAG	Additional	I write a regular foreword for European Pharmaceutical Review (EPR) on various topics of interest to readers, e.g., the role of AI in pharmaceutical industry. These articles are wholly crafted by me and EPR does not influence my output nor pay me. I regularly review articles in various journals, e.g., Journal of Pharmaceutical Sciences, Organic Process Research and Development, Journal of Chromatography. These are blind reviews and my participation isn't recorded in the published article. I'm not paid for these reviews. A new member (2025-2030) of USP small molecules group 4 and a member of USP'S mutagenic impurity compendial (MICF) framework. I will declare any conflicts of interest at the start of PCN expert group if I have involvement in USP'S discussions in that area.		
Desireen Nader Obaid	MC3 EAG	Personal	Joswe Medical (Generic) Industries	Salary	Yes
Desireen Nader Obaid	MC3 EAG	Non-Personal	NIL	N/A	N/A
Dick (Richard) Middleton	MC3 EAG	Personal	Herbal Medicines Regulatory Services Ltd	Consultancy	Yes
Dick (Richard) Middleton	MC3 EAG	Non-Personal	NIL	N/A	N/A
Donald Cairns	MC1 EAG	Personal	NIL	N/A	N/A
Donald Cairns	MC1 EAG	Non-Personal	NIL	N/A	N/A

Eamon Flahive	AIM EAG, Panel VET	Personal	Eli Lilly & Co	Shares	Yes
Eamon Flahive	AIM EAG, Panel VET	Personal	Elanco AH	Shares	Yes
Eamon Flahive	AIM EAG, Panel VET	Non-Personal	NIL	N/A	N/A
Edward Bush	BPC, MC1 EAG	Personal	AstraZeneca Pharmaceuticals	Employed by AstraZeneca as a Principal Scientist and own a limited number of shares in this company	Yes
Edward Bush	BPC, MC1 EAG	Non-Personal	NIL	N/A	N/A
Eike Reich	HCM EAG	Personal	NIL	N/A	N/A
Eike Reich	HCM EAG	Non-Personal	NIL	N/A	N/A
Eike Reich	HCM EAG	Additional			Member of PhEur Expert groups 13A, 13B, TCM WP and HOM WP until 31.10. 2025. Expert Advisor to USP BDSHM until 31.05.2025.
Elizabeth Williamson	EAG HCM, Panel VET	Personal	NIL	N/A	N/A
Elizabeth Williamson	EAG HCM, Panel VET	Non-Personal	NIL	N/A	N/A
Elliot Hook	MC2 EAG	Personal	GSK	Salary, shares	Yes
Elliot Hook	MC2 EAG	Personal	Haleon	Shares	Yes
Elliot Hook	MC2 EAG	Non-Personal	NIL	N/A	N/A

Emre Amirak	BPC, BIO EAG	Personal	Proveca Limited	Salary, Shares	Yes
Emre Amirak	BPC, BIO EAG	Personal	Vionelix Pharmaceuticals	Shares	Yes
Emre Amirak	BPC, BIO EAG	Personal	Sanofi	Shares	Yes
Emre Amirak	BPC, BIO EAG	Personal	Proveca Pharma Limited	Subsidiary of Proveca Limited	Yes
Emre Amirak	BPC, BIO EAG	Non-Personal	NIL	N/A	N/A
Faraat Ali	AIM EAG	Personal	NIL	N/A	N/A
Faraat Ali	AIM EAG	Non-Personal	NIL	N/A	N/A
Franz Schnetzinger	ATMP EAG	Personal	CEPI UK Ltd	Salary and pension entitlement	Yes
Franz Schnetzinger	ATMP EAG	Personal	Independent Consultant	Consultancy fees	Yes
Franz Schnetzinger	ATMP EAG	Non-Personal	NIL	N/A	N/A
Friederike Plath	WP BIO-DPS	Personal	F. Hoffmann-La Roche Ltd., Switzerland	Salary	Yes
Friederike Plath	WP BIO-DPS	Non-Personal	NIL	N/A	N/A
Garry Laverty	BIO EAG	Personal	Resilient Pharma Ltd	Director, launched spin-out company from Queen's University Belfast. Currently dormant.	Yes

				In place to hold any intellectual property that may arise from Dr Laverty's research.	
Garry Laverty	BIO EAG	Personal	ViiV Healthcare/GSK	Involved in using drug donated by ViiV Healthcare with my drug delivery system to explore it's use in HIV prevention.	Yes
Garry Laverty	BIO EAG	Non-Personal	NIL	N/A	N/A
Garth Hamilton	ATMP EAG	Personal	Adaptimmune	Salary	No
Garth Hamilton	ATMP EAG	Personal	Self-employed	Paid Consultant – Review of assets for a potential spin our company focusing on the development of iPSC derived allogenic cell therapies.	No
Garth Hamilton	ATMP EAG	Non-Personal	NIL	N/A	N/A
Gerard Moss	PCN EAG	Personal	WHO	Proof reading pINN lists before publication	Yes
Gerard Moss	PCN EAG	Personal	AMA	Name and structure of chemical USANs	Yes

Gerard Moss	PCN EAG	Non-Personal	NIL	N/A	N/A
Giandomenico Turchiano	ATMP EAG	Personal	AstraZeneca	Shares, Salary	Yes
Giandomenico Turchiano	ATMP EAG	Non-Personal	NIL	N/A	N/A
Giandomenico Turchiano	ATMP EAG	Additional	Inventor in patented techniques: CAST-seq and MEGA dPCR methods.		
Graham Cook	AIM EAG, MC2 EAG, AQbD WP	Personal	Pfizer	Shares, Salary	Yes
Graham Cook	AIM EAG, MC2 EAG, AQbD WP	Personal	Viatis	Shares	Yes
Graham Cook	AIM EAG, MC2 EAG, AQbD WP	Non-Personal	NIL	N/A	N/A
Greg Blake	AIM EAG	Personal	GSK	Shares & Salary	Yes
Greg Blake	AIM EAG	Non-Personal	NIL	N/A	N/A
Hannah Batchelor	CX Panel	Personal	NIL	N/A	N/A
Hannah Batchelor	CX Panel	Non-Personal	GSK	Grant awarded to support a PhD student under my supervision	Yes
Hayley Hall	BPC	Personal	Flatiron Health UK (an independent affiliate of the Roche group)	I am a lay member of the research transparency panel at Flatiron Health UK which is an independent	Yes

				affiliate of the Roche group. My role in this panel is solely related to issues of data access to Flatiron Health UK's trusted research environment of UK cancer data. Paid role.	
Hayley Hall	BPC	Non-Personal	NIL	N/A	N/A
Hayley Hall	BPC	Additional			University of Central Lancashire – from December 2020, member of the ethics community, paid role, not related to a product.
Hayley Hall	BPC	Additional			Durham University – from June 2024, member of the ethics community, unpaid role, not related to a product.
Huimin (Helen) Tao	ATMP EAG	Personal	Novartis	Salary, shares	Yes
Huimin (Helen) Tao	ATMP EAG	Personal	Sandoz group AG	Shares	Yes
Huimin (Helen) Tao	ATMP EAG	Personal	Monopar therapy	Shares	Yes
Huimin (Helen) Tao	ATMP EAG	Non-Personal	NIL	N/A	N/A
Ian Anderson	ATMP EAG	Personal	Lonza	Salary	Yes
Ian Anderson	ATMP EAG	Non-Personal	NIL	N/A	N/A
Ian Williams	AIM EAG, MC3 EAG	Personal	Viatrix	Shares	Yes

Ian Williams	AIM EAG, MC3 EAG	Non- Personal	NIL	N/A	N/A
Ishtiaq Khaliq	ATMP EAG	Personal	USB	Salary	Yes
Ishtiaq Khaliq	ATMP EAG	Non- Personal	NIL	N/A	N/A
Isobel Searing	ATMP EAG	Personal	Oxford Biomedica	Shares	Yes
Isobel Searing	ATMP EAG	Personal	Replimune Ltd	Salary, Shares	Yes
Isobel Searing	ATMP EAG	Conferences /Scientific Meetings	6 th Annual Gene Therapy Analytical Development Europe	Entrance fee	No
Isobel Searing	ATMP EAG	Non- Personal	NIL	N/A	N/A
Istvan Boros	Panel RAD	Personal	NIL	N/A	N/A
Istvan Boros	Panel RAD	Non- Personal	NIL	N/A	N/A
Jacqueline Barry	ATMP EAG	Personal	International Society for Stem Cell Research	Unpaid member of Board however receive contribution for travel and accommodation to attend Board and scientific meetings	Yes

Jacqueline Barry	ATMP EAG	Personal	MRC/BHF funded REACT programme	Steering committee member	Yes
Jacqueline Barry	ATMP EAG	Personal	Various	CGT Catapult (I am an executive director of this not for profit organisation) and ATTC network (grant funded by NIHR) collaborates with numerous industry partners, in the form of joint grant income, support for collaboration and fee-for service projects. I receive personal benefit from these	
Jacqueline Barry	ATMP EAG	Conferences /Scientific Meetings	ISSCR and other scientific conferences such as ISCT	Support towards travel and hotel	Yes
Jacqueline Barry	ATMP EAG	Non-Personal	NIL	N/A	N/A
Jacqueline Barry	ATMP EAG	Additional			Canadian Centre for Regenerative Medicine Nordic - Unpaid member of Board
Jacqueline Barry	ATMP EAG	Additional			International Society for Cell and Gene Research - Unpaid member of Audit and finance committee
James Birchall	MC2 EAG	Personal	uPatch	Member advisory board - consultancy	Yes

James Birchall	MC2 EAG	Personal	AVAXZIPEN	Member advisory board - consultancy	Yes
James Birchall	MC2 EAG	Non-Personal	NIL	N/A	N/A
James Cowie	MC2 EAG	Personal	Novartis Pharma AG	Consultancy	No
James Cowie	MC2 EAG	Personal	Novartis Pharma AG	Salary	No
James Cowie	MC2 EAG	Non-Personal	NIL	N/A	N/A
James Rickard	BPC, MC2 EAG, BLP Panel	Personal	Biotherapy Services Ltd	Shares	Yes
James Rickard	BPC, MC2 EAG, BLP Panel	Personal	Richmond Research Institute	Salary	Yes
James Rickard	BPC, MC2 EAG, BLP Panel	Non-Personal	NIL	N/A	N/A
Janet Halliday	BPC, ULM EAG	Personal	Calla Lily Clinical Care	Share options, Consultancy, Expenses	Yes
Janet Halliday	BPC, ULM EAG	Non-Personal	NIL	N/A	N/A
Janet Halliday	BPC, ULM EAG	Conference s/Scientific Meetings	DDF Berlin, Sponsor: CLCC	Expenses	No
Jasbir Rattu	ATMP EAG	Personal	RoslinCT	Consultant Qualified Person (QP)	Yes
Jasbir Rattu	ATMP EAG	Non-Personal	NIL	N/A	N/A

Jeff Aronson	PCN EAG	Personal	NIL	N/A	N/A
Jeff Aronson	PCN EAG	Non-Personal	NIL	N/A	N/A
Jeffrey Patrick	ATMP EAG	Personal	NIL	N/A	N/A
Jeffrey Patrick	ATMP EAG	Non-Personal	NIL	N/A	N/A
Jennifer Harbottle	ATMP EAG	Personal	AstraZeneca	Salary and shares	Yes
Jennifer Harbottle	ATMP EAG	Non-Personal	NIL	N/A	
Jennifer Harbottle	ATMP EAG	Additional			Member of HESI CGT-TRACS consortium imparting scientific expertise
Jigar P. Mehta	MC3 EAG	Personal	NIL	N/A	N/A
Jigar P. Mehta	MC3 EAG	Non-Personal	NIL	N/A	
Jigar P. Mehta	MC3 EAG	Additional			I would like to acknowledge, that, I am Expert Committee member of 'Small Molecule – 5' in US Pharmacopoeia Expert, Committee. In this capacity I am reviewing US Pharmacopoeial monographs and other guidance
Joao Inacio Silva	PANEL MIC	Personal	NIL	N/A	N/A
Joao Inacio Silva	PANEL MIC	Non-Personal	NIL	N/A	N/A
Joaquim Ramada-Magalhaes	ULM EAG	Personal	Lonza Biologics Plc	Salary	Yes

Joaquim Ramada-Magalhaes	ULM EAG	Personal	GSK / Haleon Plc	Shares	Yes	
Joaquim Ramada-Magalhaes	ULM EAG	Non-Personal	NIL	N/A	N/A	
John Berridge	MC1 EAG	Personal	NIL	N/A	N/A	
John Berridge	MC1 EAG	Non-Personal	NIL	N/A	N/A	
John Lough	MC1 EAG, AQbD WP	Personal	NIL	N/A	N/A	
John Lough	MC1 EAG, AQbD WP	Non-Personal	NIL	N/A		
John Lough	MC1 EAG, AQbD WP	Conference s/Scientific Meetings	Chromatographic Society Spring Symposium	No benefit to WJL (member); only to The Chromatographic Society for which WJL is a member of the Executive Committee.	No	
John Lough	MC1 EAG, AQbD WP	Additional			Yes	Interest in academic research into “modernised” pharmaceutical quality control methods. During 2025 worked primarily on flurbiprofen, chlorphenamine and baclofen related substances separations. During 2026 will be working on paroxetine related substances separations
John McGuire	PCN EAG	Personal	AstraZeneca	Employee, salary, shareholdings and dividends	Yes	
John McGuire	PCN EAG	Non-Personal	NIL	N/A	N/A	

John Miller	AIM EAG, MC2 EAG	Personal	NIL	N/A	N/A
John Miller	AIM EAG, MC2 EAG	Non- Personal	NIL	N/A	N/A
Josefina Nilsson	ATMP EAG	Personal	QuTEM AB	Shares and Salary	Yes
Josefina Nilsson	ATMP EAG	Non- Personal	NIL	N/A	N/A
Julian Smith	ULM EAG	Personal	JCS Pharma Consulting Ltd	Director, Consultant and Shareholder	Yes
Julian Smith	ULM EAG	Personal	Reckitt Benckiser Group Plc	Shares	Yes
Julian Smith	ULM EAG	Non- Personal	NIL	N/A	N/A
Ka Lung Andrew Chan	BPC	Personal	NIL	N/A	N/A
Ka Lung Andrew Chan	BPC	Conference s/Scientific Meetings	Sponsor: Joint Pharmaceutical Analysis Group (JPAG)	Free registration to JPAG meetings	No
Ka Lung Andrew Chan	BPC	Non- Personal	NIL	N/A	N/A
Ka Lung Andrew Chan	BPC	Additional	At King's College London, I give lectures on the British Pharmacopoeia (a total of 4 hours per year) at the master and undergraduate levels. I also provide training to master students on how to use and critique the BP monographs. I am an academic at King's College London and I conduct research. One of my research activities involves collaborating with a pharmaceutical company (Astra Zeneca) on a drug development project in		

which I am the joint supervisor of a PhD student (co-funded by the UKRI and AstraZeneca). The start date and duration of the project will be on the 01 Oct 2024 for 4 years. I am a committee member of a Royal Society of Chemistry interest group (the Joint Pharmaceutical and Analysis Group). I helped organising meetings (7 per year) and occasionally join as an invited speaker.					
Kaicun Zhao	HCM EAG	Personal	NIL	N/A	N/A
Kaicun Zhao	HCM EAG	Non-Personal	NIL	N/A	N/A
Karen Foster	MC2 EAG, MC3 EAG	Personal	P&G	Salary	Yes
Karen Foster	MC2 EAG, MC3 EAG	Non-Personal	NIL	N/A	N/A
Katja Strohfeldt	HCM EAG	Personal	NIL	N/A	N/A
Katja Strohfeldt	HCM EAG	Non-Personal	NIL	N/A	N/A
Keith McLuckie	ATMP EAG	Personal	NIL	N/A	N/A
Keith McLuckie	ATMP EAG	Non-Personal	NIL	N/A	N/A
Kevin Taylor	PCN EAG	Personal	NIL	N/A	N/A
Kevin Taylor	PCN EAG	Non-Personal	NIL	N/A	N/A
Kimber Barnett	AQbD WP	Personal	Pfizer	Salary, Shares	Yes
Kimber Barnett	AQbD WP	Personal	Various pharmaceutical	Shares managed by others: shares	Yes

			companies /industry	included in mutual funds and shares actively managed by advisors	
Kimber Barnett	AQbD WP	Non-Personal	NIL	N/A	N/A
Kimber Barnett	AQbD WP	Additional			Volunteer and member of the USP Expert Committee on Measurement and Data Quality
Kimberly Gilmour	ATMP EAG	Personal	NIL	N/A	N/A
Kimberly Gilmour	ATMP EAG	Conferences/ Scientific Meetings	BD Bioscience	BD FACS user meeting: Travel and lunch	No
Kimberly Gilmour	ATMP EAG	Non-Personal	Rocket	Central lab for testing for trial samples	Yes
Kimberly Gilmour	ATMP EAG	Non-Personal	Ensoma	Testing samples for potential trial eligibility and monitoring post therapy	Yes
Kimberly Gilmour	ATMP EAG	Additional			Head lab that procures starting material, store ATIMPs and issue ATIMPs for numerous non-commercial cell and gene therapy trials.
Laurent Duhau	WP BIO-DPS	Personal	Sanofi	Salary and shares	Yes
Laurent Duhau	WP BIO-DPS	Non-Personal	NIL	N/A	N/A
Leanne Di Rollo	ATMP EAG	Personal	IQVIA	Salary	Yes
Leanne Di Rollo	ATMP EAG	Non-Personal	NIL	N/A	N/A

Len Pattenden	ATMP EAG	Personal	Fondazione Telethon	Consultancy (Financial) – Head of CMC for Fondazione Telethon. Oversee portfolio programs, all CDMO activities, all early and Commercial phase manufacturing and supply chain.	Yes
Len Pattenden	ATMP EAG	Personal	Symmetric Events	Consultancy – provide training in CMC and Regulatory facets for Biotherapeutics (including ATMPs)	Yes
Len Pattenden	ATMP EAG	Personal	InnovAAVector S.r.	Consultancy – COO of the AAV CDMO	Yes
Len Pattenden	ATMP EAG	Personal	Ascend Advanced Therapies	Financial – shareholder.	Yes
Len Pattenden	ATMP EAG	Personal	CMC Biopharma Ltd	CEO – financial. Consultancies for listed activities current as of this date.	Yes
Len Pattenden	ATMP EAG	Non-Personal	NIL	N/A	N/A
Lily Li	ATMP EAG	Personal	Catapult	Salary through employment	Yes

Lily Li	ATMP EAG	Personal	AviadoBio	Salary and shares through employment	No	
Lily Li	ATMP EAG	Conference s/Scientific Meetings	Non specific	Free ticket from conference organiser	No	
Lily Li	ATMP EAG	Non-Personal	NIL	N/A	N/A	
Lily Li	ATMP EAG	Additional				Member of the Green Party (political interest). I donate to the Green Party and have allowed them to name me as a paper-only candidate in the local St Albans and District council elections. This is outside the 01-Jan-2025 and 31-Dec-2025 window of this form (Feb-2026) but added here as will be considered relevant meeting the standards reasonably expected by the public. I do not serve in any capacity to the Green Party locally or nationally, nor participate in political activities beyond what was described above for the council elections held recently.
Lincoln Tsang	BIO EAG	Personal	Ropes & Gray LLP	Legal counsel to various life sciences companies but nature and scope of the work cannot be disclosed under the professional code of conduct governing solicitors	Yes	
Lincoln Tsang	BIO EAG	Personal	Association for British Pharmaceutical Industry	Membership of advisory group	Yes	

Lincoln Tsang	BIO EAG	Personal	BioIndustry Association	Membership of advisory group	Yes
Lincoln Tsang	BIO EAG	Personal	Association for British Healthtech Industries	Auditor to non-statutory self-regulatory promotional process Membership of advisory group	Yes
Lincoln Tsang	BIO EAG	Conferences /Scientific Meetings	Independent conference organisers	Attendance of various international conferences	Yes
Lincoln Tsang	BIO EAG	Non-Personal	NIL	N/A	N/A
Lionel Randon	BIO EAG	Personal	Merck KGaA	Salary	Yes
Lionel Randon	BIO EAG	Non-Personal	NIL	N/A	N/A
Lionel Randon	BIO EAG	Additional			EDQM Expert in the MAB Working Party since 2016 and General Method Working Party since 2018 Member of EFPIA since 2009 involved in the Manufacturing & Quality, Biomanufacturing and Pharmacopoeias expert groups.
Lyn Healy	BIO EAG, ATMP EAG	Personal	NIL	N/A	N/A
Lyn Healy	BIO EAG, ATMP EAG	Non-Personal	NIL	N/A	N/A
Majella Lane	BPC, MC3 EAG, Panel IGC	Personal	NIL	N/A	N/A

Majella Lane	BPC, MC3 EAG, Panel IGC	Non-Personal	NIL	N/A	N/A
Margaret Cooper	Panel RAD	Personal	Cooper Radioisotope Solutions Ltd	Consultancy (QP for Southampton University Hospital Radiopharmacy and Richmond Pharmacology Ltd)	Yes
Margaret Cooper	Panel RAD	Non-Personal	NIL	N/A	N/A
Marius Brits	MC2 EAG	Personal	NIL	N/A	N/A
Marius Brits	MC2 EAG	Non-Personal	WHO	Financial support provided by WHO to the North-West University to provide technical assistance (laboratory work and monograph development) for the development of pharmacopoeial monographs for publication in The International Pharmacopoeia of the WHO.	Yes
Marius Brits	MC2 EAG	Conference s/Scientific Meetings	Sponsor: WHO	Travel, accommodation and per diem to attend WHO Expert Committee	Yes

				meetings in Geneva, Switzerland, as I am a member of the WHO Expert Committee on Specifications Meetings and Consultations.	
Mark Lowdell	ATMP EAG	Personal	Autolus Ltd	Consultant	Yes
Mark Lowdell	ATMP EAG	Personal	INmune Bio Inc	Co-founder, co-director, CSO, shareholder, consultant	Yes
Mark Lowdell	ATMP EAG	Personal	Avectas Ltd	Chair of SAB, Consultant	Yes
Mark Lowdell	ATMP EAG	Personal	Sartorius GmbH	Member of SAB	Yes
Mark Lowdell	ATMP EAG	Non-Personal	NIL	N/A	N/A
Martin Coxon	MC3 EAG	Personal	Custom Pharma Services	Current full time job	Yes
Martin Coxon	MC3 EAG	Non-Personal	NIL	NIL	N/A
Martin Illott	Panel VIP	Personal	Biogenesis Bago	Consultancy	Yes
Martin Illott	Panel VIP	Conferences /Scientific Meetings	TAFS forum	Right Tools, Real Impact: Evaluation and Use of FMD Vaccines and	No

				Diagnostics in the Field: Expenses (travel & accommodation)	
Martin Ilott	Panel VIP	Non-Personal	NIL	N/A	N/A
Meg Byrne	ATMP EAG	Personal	Bit.bio	Salary	Yes
Meg Byrne	ATMP EAG	Non-Personal	NIL	N/A	N/A
Melissa Hanna-Brown	AQbD WP	Personal	Pfizer	Salary	No
Melissa Hanna-Brown	AQbD WP	Personal	Pfizer	Shares	Yes
Melissa Hanna-Brown	AQbD WP	Conferences /Scientific Meetings	Royal Society of Chemistry Separation Science Group (organiser), sponsors: Shimadzu, PerkinElmer, Restek, Anthias, Expenses for travel and accommodation (I am a member of the organising committee and was a speaker at the event).	Solutions in Science 2025 Brighton: Expenses for travel and accommodation (I am a member of the organising committee and was a speaker at the event	No

			Verder, Da Vinci, element, CEM, JEOL, Verdel, Waters, UVision, Labware, Elite, Agilent, Haier Biomedical, VUV analytics, Vici, Metrohm, Bruker, Verulam, FOSS, Merck			
Melissa Hanna-Brown	AQbD WP	Conferences /Scientific Meetings	Shimadzu, CatSci, Spectrometrics	Sustainable Analytical Science: Expenses for travel	No	
Melissa Hanna-Brown	AQbD WP	Non-Personal	CAMS (Community for Analytical Measurement Science) Astra Zeneca, Pfizer, Syngenta, Shimadzu, Waters, GSK, Anthias, Agilent	All monies CAMS receives (industry sponsorship and charity grants from the Analytical Chemistry Trust Fund) are spent on the work of CAMS (secretariat and PhD/Postdoc projects/events).	Yes	Exec board chair and co-founder of CAMS industry led network for analytical measurement science. The network is a 'bridging' community to enable industry to bring measurement challenges to the academic community and seek solutions through collaborations (PhD and postdoc). I receive no payment from CAMS (I am a volunteer). Industry members including Astra Zeneca, Pfizer, Syngenta, Shimadzu, Waters, GSK, Anthias, Agilent and other SMEs (the network is continually growing) have sponsored the network and other companies may come on board during the period of my chairing
Melissa Hanna-Brown	AQbD WP	Non-Personal	Pfizer	Postdoctoral research grant to support work in my research group on predictive chromatography.	No	

				Financial support to support her salary and the project research costs (columns, solvents, compounds, materials, modelling software)	
Michael Themis	ATMP EAG	Personal	Testavec Ltd	Shares	Yes
Michael Themis	ATMP EAG	Conferences /Scientific Meetings	Testavec Ltd	British Society for Gene and Cell Therapy: Expenses/fees	No
Michael Themis	ATMP EAG	Conferences /Scientific Meetings	Testavec Ltd	European Society for Gene and Cell Therapy: Expenses/fees	No
Michael Themis	ATMP EAG	Conferences /Scientific Meetings	Brunel University London	Gene Therapy Workshop & Consensus Paper: Expenses/fees	No
Michael Themis	ATMP EAG	Conferences /Scientific Meetings	Brunel University London	NC3RS-BBSRC Business Interaction Vouchers Networking Event: Expenses/fees	No
Michael Themis	ATMP EAG	Conferences /Scientific Meetings	Testavec Ltd	Joint MHRA/NC3RS/AB PI Workshop: Incorporation Of New Approach	No

				Methodologies (NAMS) to support the development of new medicines: Expenses/fees	
Michael Themis	ATMP EAG	Conferences /Scientific Meetings	Testavec Ltd	British Society Of Toxicological Pathology: Expenses/fees	No
Michael Themis	ATMP EAG	Non-Personal	GSK	Consultancy	No
Michael Themis	ATMP EAG	Non-Personal	Testavec Ltd	CSO	Yes
Michel Degueldre	ATMP EAG	Personal	UCB	Salary	Yes
Michel Degueldre	ATMP EAG	Non-Personal	NIL	N/A	N/A
Michel Degueldre	ATMP EAG	Additional			I am an effective member of the Belgian Society for Mass Spectrometry (BSMS). The Society receives sponsorship from many sources for its annual congress. These funds are shared between the local organising committee who run the conference and BSMS to grant students for international congress attendance and to promote mass spectrometry in general.
Miriam Guest	Panel MIC	Personal	AstraZeneca	Employee	No
Miriam Guest	Panel MIC	Personal	AstraZeneca	Shareholder	Yes
Miriam Guest	Panel MIC	Personal	Charles River Labs, Microbial Solutions	Employee	Yes

Miriam Guest	Panel MIC	Non-Personal	NIL	N/A	N/A
Mohamed Abdelhamid Ali	MC2 EAG	Personal	Sunny Pharmaceutical	Salary	Yes
Mohamed Abdelhamid Ali	MC2 EAG	Non-Personal	USP	Expert Volunteer SM4	Yes
Mohamed Abdelhamid Ali	MC2 EAG	Conference s/Scientific Meetings	Sunny Pharmaceutical	Expenses	Yes
Monique Simmonds	BPC, HCM EAG	Personal	Polypharmakos Limited	Director, no financial etc interest	Yes
Monique Simmonds	BPC, HCM EAG	Conference/Scientific Meetings	Sponsor: Proctor and Gamble	Costs for travel covered	No
Monique Simmonds	BPC, HCM EAG	Non-Personal	P&G	Master collaboration agreement grant (no personal consultancy)	Yes
Monique Simmonds	BPC, HCM EAG	Additional			Member of Defra Darwin Initiative Advisory Committee no financial etc interest
Monique Simmonds	BPC, HCM EAG	Additional			Member of Grantham Centre for Sustainable Futures, no financial etc interest
Monique Simmonds	BPC, HCM EAG	Additional			Past President of Good Practice Traditional Chinese Medicine Research Association, no financial etc interest
Monique Simmonds	BPC, HCM EAG	Additional			Chair of Hilliers Gardens Trust Advisory Board, no financial etc interest

Monique Simmonds	BPC, HCM EAG	Additional				Member of Hong Kong Dept of Health, Pharmacopoeia International Advisory Committee, no financial etc interest
Monique Simmonds	BPC, HCM EAG	Additional				Member of Responsible Beauty Advisory Council (P&G), no financial etc interest
Monique Simmonds	BPC, HCM EAG	Additional				Member of Royal Holloway University of London Department of Health Advisory Board, no financial etc interest
Mustafa Zaman	AQbD WP	Personal	Granzer Regulatory Consulting and Services Gmbh, Germany. https://www.granzer.biz/index.html	Employee	Yes	
Mustafa Zaman	AQbD WP	Conferences /Scientific Meetings	King's College London	MPharm undergraduate (3rd year) lecture, presented lecture 'on-line'. No fees/expenses received.	No	
Mustafa Zaman	AQbD WP	Conferences/ Scientific Meetings	King's College London	Pharmaceutical sciences MSc course lecture, presented lecture. No fees/expenses received.	No	
Mustafa Zaman	AQbD WP	Non-Personal	NIL	N/A	N/A	
Mustafa Zaman	AQbD WP	Additional				Lecturer (honorary) at Kingston University. This is an unpaid post.

Mustafa Zaman	AQbD WP	Additional				Visiting (Honorary) senior lecturer at King's College London for both MPharm and MSc programmes. This is an unpaid post.
Mustafa Zaman	AQbD WP	Additional				Senior Lecturer (honorary) De Montfort University. This is an unpaid post.
Mustafa Zaman	AQbD WP	Additional				Member Centre of Pharmaceutical Medicine Research (CPMR) Scientific Advisory Board, King's College London. This is an unpaid post. Did not attend any meetings between 1 January 2025 and 31 December 2025
Oisin Kavanagh	BPC,CX Panel, PCN EAG	Personal	Thiogenesis Inc	Research grant, £22,213	No	
Oisin Kavanagh	BPC,CX Panel, PCN EAG	Personal	Newcastle University	Patent application	Yes	
Oisin Kavanagh	BPC,CX Panel, PCN EAG	Non-Personal	NIL	N/A	N/A	
Paolo Tozzi	BIO EAG, ATMP EAG	Personal	Moderna	Shares	Yes	
Paolo Tozzi	BIO EAG, ATMP EAG	Personal	Novartis	Shares	Yes	
Paolo Tozzi	BIO EAG, ATMP EAG	Personal	Sandoz	Shares	Yes	
Paolo Tozzi	BIO EAG, ATMP EAG	Conferences /Scientific Meetings	USP	Part of the USP mRNA committee	No	

Paolo Tozzi	BIO EAG, ATMP EAG	Conferences /Scientific Meetings	DQM	Part of the EDQM, CTP, GTP and mRNA committee	No
Paolo Tozzi	BIO EAG, ATMP EAG	Non-Personal	NIL	N/A	N/A
Patrick Jackson	AQbD WP	Personal	GSK	Salary and Shareholder	Yes
Patrick Jackson	AQbD WP	Conferences /Scientific Meetings	GSK	Royal Society of Chemistry: Associate Membership fees	Yes
Patrick Jackson	AQbD WP	Conferences /Scientific Meetings	PharmaLab 2024	Conference presentation – Analytical Quality by Design Application to Analytical Procedure Lifecycle	Yes
Patrick Jackson	AQbD WP	Non-Personal	NIL	N/A	N/A
Patrick Jackson	AQbD WP	Additional			European Compliance Academy – Analytical Quality Control Group – Volunteer Member
Patrick Jackson	AQbD WP	Additional			International Consortium for Innovation and Quality in Pharmaceutical Development – Analytical Quality by Design Working Group – Volunteer Member (although the group has not been active in a while)
Paul Anderson	HCM EAG	Personal	GR Lane Health Products Ltd	Salary	Yes
Paul Anderson	HCM EAG	Non-Personal	NIL	N/A	N/A

Paul Carter	ATMP EAG	Personal	Quell Therapeutics	Salary and bonus	Yes
Paul Carter	ATMP EAG	Personal	Quell Therapeutics	Shares	Yes
Paul Carter	ATMP EAG	Personal	GSK	Shares	Yes
Paul Carter	ATMP EAG	Personal	AstraZeneca	Shares	Yes
Paul Carter	ATMP EAG	Personal	Haleon	Shares	Yes
Paul Carter	ATMP EAG	Non-Personal	NIL	N/A	N/A
Paul Fleming	MC1 EAG	Personal	Medicines UK (formerly BGMA, British Generic Manufacturers Association)	Technical Director of a pharmaceutical industry trade association	Yes
Paul Fleming	MC1 EAG	Non-Personal	NIL	N/A	N/A
Paul Getty	ATMP EAG	Personal	Pharmaron Biologics	Salary	Yes
Paul Getty	ATMP EAG	Conferences /Scientific Meetings	Refeyn	Refeyn user group: expenses	No
Paul Getty	ATMP EAG	Non-Personal	NIL	N/A	N/A
Paul Marshall	BPC, MC1 EAG, Panel RAD, CX Panel	Personal	Jazz Pharmaceuticals	Shares & Employment	No

Paul Marshall	BPC, MC1 EAG, Panel RAD, CX Panel	Personal	Reckitt Benckiser Plc	Shares	Yes
Paul Marshall	BPC, MC1 EAG, Panel RAD, CX Panel	Personal	Otsuka Pharmaceutical s Europe Ltd	Shares & Employment	Yes
Paul Marshall	BPC, MC1 EAG, Panel RAD, CX Panel	Personal	Individior	Shares	Yes
Paul Marshall	BPC, MC1 EAG, Panel RAD, CX Panel	Non- Personal	NIL	N/A	
Paul Marshall	BPC, MC1 EAG, Panel RAD, CX Panel	Conference s/Scientific Meetings	Sponsor:Topra	Presenter Expenses	No
Paul Varley	BIO EAG, BLP Panel, WP BIO- DPS	Personal	Sanofi	Shares	Yes
Paul Varley	BIO EAG, BLP Panel, WP BIO- DPS	Non- Personal	NIL	N/A	N/A

Peng Wang	ATMP EAG	Personal	Lonza	Salary	Yes
Peng Wang	ATMP EAG	Non- Personal	NIL	N/A	N/A
Peter Emery- Billcliff	ATMP EAG	Personal	GSK	Shares	Yes
Peter Emery- Billcliff	ATMP EAG	Personal	Haleon	Shares	Yes
Peter Emery- Billcliff	ATMP EAG	Personal	Complement Therapeutics	EMI Share Option and Salary	Yes
Peter Emery- Billcliff	ATMP EAG	Conferences/ Scientific Meetings	Sartorius ThermoFisher Scientific 10x Genomics Acro Biosystems Beckman Coulter Fluidic Sciences GenScript Nova Biomedical ...and many more	Cell UK 2025	No
Peter Emery- Billcliff	ATMP EAG	Non- Personal	NIL	N/A	N/A
Peter Hamilton	AQbD WP	Personal	AstraZeneca	Salary, Shares	Yes
Peter Hamilton	AQbD WP	Non- Personal	NIL	N/A	N/A
Peter Henrys	Panel IGC	Personal	BOC Ltd.	Salary	Yes
Peter Henrys	Panel IGC	Non- Personal	NIL	N/A	N/A

Peter Henrys	Panel IGC	Additional			Chairman Of The European Pharmacopoeia 9g Medical Gas Committee, Chairman Of British Compressed Gas Association (Bcga) Medical Gas Committee (Tsc7), Member Of European Industrial Gas Association (Eiga) Medical Gas Committee (Wg7) And Medical Gas Equipment Committee (Wg15) And Associated Ad Hoc Committees, Chairman Of Bsi Ch 121 / Sc6 Standards Committee (Medical Gas Supply Systems), Member Of Iso Tc 121 / Sc6 Standards Committee (Medical Gas Supply Systems), Member Of The Association Of Anesthetists Safety Committee, Financial Director (Non-Paid) Of Barema (British Anaesthetic And Respiratory Equipment Manufacturing Association)
Phil Hampshire	MC3 EAG	Non-Personal	NIL	N/A	N/A
Phil Hampshire	MC3 EAG	Personal	Accord Healthcare	Salary	Yes
Phil Hampshire	MC3 EAG	Non-Personal	NIL	N/A	N/A
Phil Nethercote	AQbD WP	Personal	NIL	N/A	N/A
Phil Nethercote	AQbD WP	Non-Personal	NIL	N/A	N/A
Ralph Woodland	Panel VIP	Personal	NIL	N/A	N/A
Ralph Woodland	Panel VIP	Non-Personal	NIL	N/A	N/A
Ramon Mendoza	ATMP EAG	Personal	NIL	N/A	N/A
Ramon Mendoza	ATMP EAG	Non-Personal	NIL	N/A	N/A

Rebekka Hueting	Panel RAD	Personal	NIL	N/A	N/A
Rebekka Hueting	Panel RAD	Non-Personal	NIL	N/A	N/A
Rehma Chandaria	ATMP EAG	Personal	NIL	N/A	N/A
Rehma Chandaria	ATMP EAG	Non-Personal	NIL	N/A	N/A
Richard Cawthorne	CX Panel	Personal	Croda International Plc	Shares	Yes
Richard Cawthorne	CX Panel	Personal	Croda International Plc	Consultancy	Yes
Richard Cawthorne	CX Panel	Personal	Croda International Plc	Salary	Yes
Richard Cawthorne	CX Panel	Non-Personal	NIL	N/A	N/A
Rickard Nordstrom	ATMP EAG	Personal	QuTEM AB	Shares and Salary	Yes
Rickard Nordstrom	ATMP EAG	Non-Personal	NIL	N/A	N/A
Rita Rego	ATMP EAG	Personal	Virocell Biologics Ltd, Virocell Holdings Ltd	Salary and Shares	Yes
Rita Rego	ATMP EAG	Personal	Qualis Pharma Solutions Ltd	Director of the company	Yes
Rita Rego	ATMP EAG	Non-Personal	NIL	N/A	N/A

Robert Lowe	BPC, PCN EAG, ULM EAG	Personal	Baxter Healthcare	Personal non-specific interest – consultancy on branding and product usage	Yes
Robert Lowe	BPC, PCN EAG, ULM EAG	Non-Personal	NIL	N/A	N/A
Robin Thorpe	BIO EAG, PCN EAG	Personal	NIL	N/A	N/A
Robin Thorpe	BIO EAG, PCN EAG	Non-Personal	NIL	N/A	N/A
Rodney Horder	AIM EAG, PCN EAG	Personal	Blackrock Pharmaceuticals	Consultancy	Yes
Rodney Horder	AIM EAG, PCN EAG	Non-Personal	NIL	N/A	N/A
Roger Pickett	Panel RAD	Personal	GE Healthcare	Shares & Pension	Yes
Roger Pickett	Panel RAD	Personal	GE Healthcare	Immediate family member holds shares	Yes
Roger Pickett	Panel RAD	Non-Personal	NIL	N/A	N/A
Ronald Torano	MC3 EAG	Personal	GSK	Shares	Yes
Ronald Torano	MC3 EAG	Non-Personal	NIL	N/A	N/A
Rosario LoBrutto	AQbD WP	Personal	Ironwood	Shares, Salary, Grants	Yes
Rosario LoBrutto	AQbD WP	Personal	Pharma Vision LLC	Consultancy	Yes

Rosario LoBrutto	AQbD WP	Personal	Chair Biologic USP Expert Committee	USP Chair Expert Committee (volunteer)	Yes
Rosario LoBrutto	AQbD WP	Non-Personal	NIL	N/A	N/A
Ruben Thanacoody	HCM EAG	Personal	NIL	N/A	N/A
Ruben Thanacoody	HCM EAG	Non-Personal	NIL	N/A	N/A
Sabine Domning	ATMP EAG	Personal	NIL	N/A	N/A
Sabine Domning	ATMP EAG	Non-Personal	NIL	N/A	N/A
Sam Brocklehurst	ATMP EAG	Personal	Pharmaron	Salary, Shares	Yes
Sam Brocklehurst	ATMP EAG	Non-Personal	NIL	N/A	N/A
Sarah Cockbill	Panel VET	Personal	NIL	N/A	N/A
Sarah Cockbill	Panel VET	Non-Personal	NIL	N/A	N/A
Sarah Hartley	ULM EAG	Personal	Rosemont Pharmaceuticals Ltd	Salary	Yes
Sarah Hartley	ULM EAG	Non-Personal	NIL	N/A	N/A
Seamus Boland	MC1 EAG, Panel IGC	Personal	NIL	Shares	No
Seamus Boland	MC1 EAG, Panel IGC	Non-Personal	NIL	Salary	No

Seamus Boland	MC1 EAG, Panel IGC	Conference s/Scientific Meetings	NIL	Shares (immediate family member)	No
Seamus Boland	MC1 EAG, Panel IGC	Additional	NIL	Shares (immediate family member)	No
Sean Jones	BPC, AIM EAG, AQbD WP	Personal	NIL	N/A	N/A
Sean Jones	BPC, AIM EAG, AQbD WP	Non-Personal	NIL	N/A	
Sean Jones	BPC, AIM EAG, AQbD WP	Additional			Family member is a QC analyst working for Catalent in Swindon.
Simeon Gill	BIO EAG	Personal	AstraZeneca	Salary and Shares	Yes
Simeon Gill	BIO EAG	Non-Personal	NIL	N/A	N/A
Simeon Gill	BIO EAG	Additional			Member of ISPE RHQC EMEA affiliate Participating member of EFPIA biomanufacturing MQEG for PACMP Participating member of EFPIA MQEG Acceleration /Prime/Covid
Stephen Ellison	AQbD WP	Personal	LGC (Teddington) limited (Employer)	Salary and shares in LGC group	Yes
Stephen Ellison	AQbD WP	Non-Personal	NIL	N/A	N/A
Steven Nolan	MC1 EAG	Personal	United QP Consulting Ltd	Act as contract Qualified Person on behalf of United QP consulting for	Yes

				CP Pharmaceuticals/ Wockhardt UK	
Steven Nolan	MC1 EAG	Non- Personal	NIL	N/A	N/A
Stuart Paul- Adams	ULM EAG	Personal	NIL	N/A	N/A
Stuart Paul- Adams	ULM EAG	Non- Personal	NIL	N/A	N/A
Sushmita "Mimi" Roy	ATMP EAG	Personal	NIL	N/A	N/A
Sushmita "Mimi" Roy	ATMP EAG	Non- Personal	NIL	N/A	N/A
Tina Morris	AQbD WP	Personal	NIL	N/A	N/A
Tina Morris	AQbD WP	Non- Personal	NIL	N/A	N/A
Tishwant Kanwarjit	ATMP EAG	Personal	NIL	N/A	N/A
Tishwant Kanwarjit	ATMP EAG	Non- Personal	NIL	N/A	N/A
Varada Bapat	MC1 EAG	Personal	RV Lifesciences LTD	Salary	Yes
Varada Bapat	MC1 EAG	Conference s/Scientific Meetings	NIL	N/A	N/A
Varada Bapat	MC1 EAG	Non- Personal	NIL	N/A	N/A
Vikas Jaitely	BPC, AIM EAG, Panel MIC	Personal	Merck Biopharma (Ares Trading	Salary (permanent employee)	Yes

			SA- subsidiary of Merck Group Germany)		
Vikas Jaitely	BPC, AIM EAG, Panel MIC	Non- Personal	NIL	N/A	N/A
Wayne Goddard	ATMP EAG	Personal	North Tees and Hartlepool NHSFT	Salary	Yes
Wayne Goddard	ATMP EAG	Personal	Manchester University	Visiting Lecturer fees	Yes
Wayne Goddard	ATMP EAG	Non- Personal	NIL	N/A	N/A
Wei Wang	ATMP EAG	Personal	NIL	N/A	N/A
Wei Wang	ATMP EAG	Non- Personal	NIL	N/A	N/A
Yvonne Perrie	BPC, MC3 EAG	Personal	NIL	N/A	N/A
Yvonne Perrie	BPC, MC3 EAG	Additional	Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS)	I am Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). We are an internationally leading technological University and as such we work with many companies across the dept, faculty and University. We also work with Health care providers including a wide range of NHS trusts and pharmacies through both research and education.	
Yvonne Perrie	BPC, MC3 EAG	Non- Personal	Precision Nanomedicines Inc	Knowledge exchange research contracts from company to University of Strathclyde and	No

				joint PhD funding. Equipment loan to University of Strathclyde to support project.	
Yvonne Perrie	BPC, MC3 EAG	Non- Personal	Micropore Technologies Ltd	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde. Innovate UK grant.	No
Yvonne Perrie	BPC, MC3 EAG	Non- Personal	Centre for process Innovation Ltd	Research Grant to University of Strathclyde.	No
Yvonne Perrie	BPC, MC3 EAG	Non- Personal	Imperial College London	Research Collaborator:	No
				VaxHub Grant to University of Strathclyde.	No
Yvonne Perrie	BPC, MC3 EAG	Non- Personal	Microfluidics Inc	Equipment loan to University of Strathclyde and in- kind research support (consumables).	No
Yvonne Perrie	BPC, MC3 EAG	Non- Personal	Avanti polar lipids/Croda	BBSRC Icase PhD studentship	No

				grant to University of Strathclyde	
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	AstraZeneca	PhD studentships including lcase.	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Defence Threat Reduction Agency DTRA (administered by DSTL)	Research Grant to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Target Healthcare	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Boehringer Ingelheim	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Takeda / Millenium Pharmaceuticals	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	LEON Nano Drugs GmbH	Knowledge exchange research contracts from company to University of Strathclyde	No

Yvonne Perrie	BPC, MC3 EAG	Non-Personal	NOF Corporation	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	ABITEC	joint PhD funding.	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Phillips Medisize, a molex company	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	N4 Pharma	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Syncona Ltd	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Micropore ABITEC AstraZeneca Colorcon Croda	PhD CDT Training programme where I am Co-I. CMAC CEDAR - https://www.cmac.ac.uk/cedar	No
Yvonne Perrie	BPC, MC3 EAG	Non-Personal	Pfizer Sanofi	Whilst not directly linked to my	No

			Chiesi UCB Takeda Lilly Roche	Nanomedicines theme in the PhD CDT programme, other companies are linked to the grant.	
Zara Hannoun	ATMP EAG	Personal	Zelluna Therapeutics	Salary	Yes
Zara Hannoun	ATMP EAG	Non- Personal	NIL	N/A	N/A
Zena Smith	MC2 EAG	Personal	Jazz Pharmaceuticals	Shares and Salary	Yes
Zena Smith	MC2 EAG	Non- Personal	NIL	N/A	N/A

Contact information about these reports:

Medicines and Healthcare products Regulatory Agency
Customer Services
10 South Colonnade
Canary Wharf
London E14 4PU

Tel: 020 3080 6000

E-mail: info@mhra.gov.uk

© Crown copyright 2026

Published by the Medicine and Healthcare products Regulatory Agency

ISBN 978-1-8384147-5-7

Guidance on reproducing and re-using MHRA Crown copyright material can be found on our website at:
<http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/copyright-and-re-use/crown-copyright/>